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CHAPTER - I 
INTRODUCTION 
Most of the drugs are administered through the oral route; it has always been 
preferred route for the formulators over other routes. But this route is limited to such 
drug molecules which has poor aqueous solubility, which is one of the important 
parameters to achieve desired concentration of drug in systemic circulation for 
desired (anticipated) pharmacological response. A large number of potential drug 
candidates suffer from low aqueous solubility and low dissolution rate. This leads to 
low drug concentration at the absorption site and results in low oral bio availability. 
In BCS classification system these poor solubility drugs are classified as BCS class 
II drugs.  
                                   Biopharmaceutical Classification System (BCS): 
 
                Biopharmaceutics Classification System (BCS) was introduced in 1995 as a 
basis for predicting the likelihood of In vitro-In vivo correlations for immediate release 
dosage forms. BCS has been used as a regulatory Tool for  the replacement of certain 
bioequivalence (BE) studies with accurate in vitro dissolution tests. This step certainly 
reduces timelines in the drug development process, both directly and indirectly, and 
reduces unnecessary drug exposure in healthy volunteers. 
The BCS also takes account of the dissolution of the  drug product and hence covers 
the three main factors which govern the rate and extent of drug absorption from 
immediate release (IR) solid oral dosage forms. 
• Dissolution rate 
• Solubility 
• Permeability 
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Solubility: 
           Solubility is defined as the maximum amount of solute that can be dissolved in a 
given amount of solvent. Quantitatively it is defined as “the concentration of the solute 
in a saturated solution at a certain temperature. Qualitatively the solubility may be 
defined as an interaction of two or more substances to form homogenous molecular 
dispersion. Solubility of a drug plays a prime role in controlling its dissolution from 
dosage form. Aqueous solubility of a drug is a major factor which determines its 
dissolution rate. 
A drug substance is considered highly soluble when the highest dose strength is 
soluble in 250 ml or less of aqueous media over a pH range of 1 to 7.5 (equilibrium 
solubility at 37°C).  
Permeability: 
            In the absence of evidence suggesting instability in the gastrointestinal tract, a 
drug substance is considered highly permeable when the extent of absorption in 
humans is determined to be 90% or more of an administered dose based on mass 
balance determination or in comparison to an intravenous reference dose (absolute 
bioavailability study). 
                                               TABLE: BCS classification 
 
 solubility permeability 
Class I High solubility High permeability 
Class II Low solubility High permeability 
Class III High solubility Low permeability 
    Class IV  Low solubility Low permeability 
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Class I Drugs 
Class I drugs exhibit a high absorption and a high dissolution. The rate 
limiting step is drug dissolution. Gastric emptying rate becomes  the  rate  
determining step if dissolution is very rapid. Generally 85% drug is released 
within 15 min dissolution study. According to FDA (1997) guideline, 
bioavailability and bioequivalence studies are unnecessary for such products. 
IVIVC would not be expected for these drugs. Examples include amitriptyline 
hydrochloride, chloroquine phosphate, chlorpheniramine maleate, 
chlorpromazine hydrochloride, cloxacillin sodium, phenytoin sodium, 
prednisolone, promethazine, propranolol hydrochloride, quinine sulfate, 
verapamil hydrochloride and warfarin sodium etc (Kasim et al. 2004). 
Class II Drugs 
Class II drugs have a high absorption but a low dissolution rate. In-vivo drug 
dissolution is then a rate limiting step for absorption except at a very high dose 
number. These drug exhibited variable bioavailability and need the enhancement in 
dissolution for increasing the bioavailability. In vitro- In vivo correlation (IVIVC) is 
usually expected for class II drugs. 
Examples include phenytoin. danazol, ketoconazole, mefenamic acid, 
nifedinpine. felodipine, nicardipine, nisoldipine, atorvastatin calcium, simvastatin, 
rosuvastatin calcium etc (Kasim et al. 2004). 
Class III Drugs 
Permeability is rate limiting step for drug absorption of class III drugs. These 
drugs exhibit a high variation in the rate and extent of drug absorption. Since the 
dissolution is rapid, the variation is attributable to alteration of physiology and 
membrane permeability rather than the dosage for factors. These drugs are 
problematic for controlled release development. These drugs showed the low 
bioavailability and need enhancement in permeability.  
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Examples include cimitidine, ranitidine, acyclovir, alendronate, captopril, 
enalaprilat neomycin B, atenolol etc (Kasim et al. 2004). 
Class IV Drugs 
Class IV drugs exhibit poor and variable bioavailability. Several factors such as 
dissolution rate, permeability and gastric emptying are the rate limiting steps for the 
drug absorption. These drugs are not suitable for controlled release formulation. 
Examples include acetazolamide, allopurinol, dapsone, doxycycline, nalidixic acid, 
sulfadiazine, sulfamethoxazole, trimethoprim etc (Kasim et al. 2004). 
  So oral route is not advisable for these poorly soluble drugs, which may be 
inefficient to achieve desired drug concentration on the site of action due to its poor 
solubility and dissolution. 
METHODS TO OVER COME SOLUBILITY PROBLEMS: 
 Different formulation approaches like micronization, solid dispersion, and 
complexation with cyclodextrins have come up for the oral bioavailability of poorly 
water soluble drugs.  Indeed, in some selected cases, these approaches have been 
successful but they offer many other disadvantages. The main problem with 
micronization is chemical / thermal stability. Many drugs may degrade and lose 
bioactivity when they are micronized by conventional method. For solid dispersion the 
amount of carriers used is often large, and thus if the dose of active ingredient is high, 
the tablets or capsules formed will be large in volume and difficult to swallow. 
Moreover, since the carriers used are usually expensive and freeze-drying or spray- 
drying method requires particular facilities and processes, leading to high production 
cost. Though, traditional solvent method can be adopted instead, it is difficult to deal 
with co- precipitates with high viscosity. Complexation with cyclodextrins techniques is 
not applicable for drug substances which are not soluble in both aqueous and organic 
solvents.  
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 In many cases oral bioavailability of poor water soluble drugs may be enhanced 
when co- administered with meal rich in fat has led to increasing recent interest in the 
formulation of poorly water soluble drugs in lipids. Lipid suspension, solutions and 
emulsions have all been used to enhance the oral bioavailability but, more recently 
there have been much focus on the utility of self-microemulsifying drug delivery 
systems (SMEDDS).  
SELF DISPERSING LIPID FORMULATION SYSTEM: 
       Various delivery systems for the lipophilic drugs are available such as 
microemulsion, lipid solution, lipid emulsion, dry emulsion, whose formulation involve 
large number of possible combination of excipient, so to understand these lipid based 
formulation a classification namely “ Lipid formulation classification system have been 
introduced by Pouton in 2000 and recently updated (2006). 
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Figure: Diagramatic illustration of Lipid based formulation 
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Lipid formulation mainly comprises of  
• Macro emulsion 
• Micro emulsion 
• Self micro emulsifying drug delivery system (SMEDDS). 
• Solid –lipid nano particle(SLN), 
• Liposomes and 
• Lipolexes. 
 
 In recent years, much attention has been focused on lipid based formulation, with 
particular emphasis on SMEDDS. 
Classification of lipid formulation system: 
               According to the composition and the effect of dilution and digestion on the 
ability to prevent precipitation of drug, lipid based formulations  are broadly classified 
into four categories. 
• Type I formulation 
• Type II formulation 
• Type III formulation, and  
• Type IV formulation 
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Formulati
on type 
 
Oil;tri,di 
&mono 
glycerides 
Water-
insoluble 
surfactants 
Water-
soluble 
surfactan
ts 
Hydrophili
c 
cosolvent
s 
Type of 
dispersi
on 
Digestion 
requiremen
t 
Type I oil 100 - - - Limited 
or no 
dispersio
n 
Requires 
digestion 
Type II SEDD
S 
40-80 20-60 - - Rapidly 
dispersin
g 
Likely to be 
digested 
Type III III A 
SEDD
S 
40-80 - 20-40 0-40 Rapidly 
dispersin
g 
Digestion 
may not be 
necessary 
III B 
SMED
DS 
<20  20-50 20-50 Transpar
ent 
dispersio
n 
Digestion 
may not be 
necessary 
Type IV Oil 
free 
- 0-20 30-80 0-50 Miscellar 
solution 
Limited 
digestion 
 
Type I systems consist of formulations which comprise drug in solution in 
triglycerides and/or mixed glycerides or in oil-in-water emulsion stabilized by low 
concentrations of emulsifiers such as 1% (w/v) polysorbate 60 and 1.2% (w/v) lecithin. 
Generally, these systems exhibit poor initial aqueous dispersion and require digestion 
by pancreatic lipase/ co- lipase in the GIT to generate more amphiphilic lipid digestion 
products and promote drug transfer into the colloidal aqueous phase. Type I lipid 
formulations therefore represent a relatively simple formulation option for potent drugs 
or highly lipophilic compounds where drug solubility in oil is sufficient to allow 
incorporation of the required payload (dose). 
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Type II lipid formulations constitute SEDDS. Self-emulsification is generally 
obtained at surfactant contents above 25% (w/w). However at higher surfactant 
contents (greater than 50– 60% (w/w) depending on the materials) the progress of 
emulsification may be compromised by the formation of viscous liquid crystalline gels at 
the oil/water interface. Type II lipid- based formulations provide the advantage of 
overcoming the slow dissolution step typically observed with solid dosage forms and as 
described above generate large interfacial areas which in turn allows efficient 
partitioning of drug between the oil droplets and the aqueous phase from where 
absorption occurs.  
Type III lipid-based formulations, commonly referred to as self-microemulsifying 
drug delivery systems (SMEDDS), are defined by the inclusion of hydrophilic 
surfactants (HLB>12) and co-solvents such as ethanol, propylene glycol and 
polyethylene glycol. Type III formulations can be further segregated (somewhat 
arbitrarily) into Type IIIA and Type IIIB formulations in order to identify more hydrophilic 
systems (Type IIIB) where the content of hydrophilic surfactants and co-solvents 
increases and the lipid content reduces. Type IIIB formulations typically achieve 
greater dispersion rates when compared with Type IIIA although the risk of drug 
precipitation on dispersion of the formulation is higher given the lower lipid content.  
Type IV: In order to capture the recent trend towards formulations which contain 
predominantly hydrophilic surfactants and co-solvents, this category was recently 
added. Type IV formulations do not contain natural lipids and represent the most 
hydrophilic formulations. These formulations commonly offer increased drug payloads 
when compared to formulations containing simple glyceride lipids and also produce 
very fine dispersions when introduced in aqueous media. Little is known however, as to 
the solubilisation capacity of these systems In vivo and in particular whether they are 
equally capable of maintaining poorly water soluble drug in solution during passage 
along the GIT when compared with formulations comprising natural oils (Type II and 
Type III). An example of a Type IV formulation is the current capsule formulation of the 
HIV protease inhibitor amprenavir (Agenerase) which contains TPGS as a surfactant 
and PEG 400 and propylene glycol as co- solvents.  
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Self Micro Emulsifying Drug Delivery System (SMEDDS) 
The self emulsifying drug delivery system (SEDDS), are well known for their 
potential as alternative approach for delivery of hydrophobic drugs, which are 
associated with poor water solubility and low oral bioavailability . SEDDSs are 
isotropic and thermodynamically stable solutions consisting of oil, surfactant, co-
surfactant and drug mixtures that spontaneously form oil-in-water (o/w) emulsion 
when mixed with water under gentle stirring. The motility of stomach and intestine 
provides the agitation required for self- emulsification in-vivo. This spontaneous 
formation of an emulsion in the gastrointestinal tract presents the drug in a 
solubilized form, and the small size of the formed droplet provides a large interfacial 
surface area for drug absorption . Apart from solubilization, the presence of lipid in 
the formulation further helps to improve bioavailability by enhancing the drug 
absorption. Selection of a suitable self-emulsifying formulation depends upon the 
assessment of the solubility of the drug in various components and the droplet size 
distribution of the resultant emulsion following self-emulsification. SEDDS are 
mostly prepared in liquid dosage form in soft and hard gelatin capsules. Solid 
SEDDS are new approach to make solid dosage form such as tablets, capsules etc. 
Here it is essential to understand the differences between microemulsion 
and nano emulsions SMEDDS finally forms microelmulsion after oral administration. 
Micro emulsions are isotropic, thermodynamically stable systems composed of oil, 
water, surfactant and co-surfactants or co-solvents. The main driving force for 
microemulsion formation is the ultra low interfacial tension, which is usually 
achieved by the use of two or more emulsifiers (surfactant and co-surfactant). Out 
of the two emulsifiers used, one is essentially water soluble (surfactant) and the 
other one is oil soluble (co-surfactant). 
   Now a days SMEDDS has emerged as a vital strategy to formulate poor 
soluble compounds for bioavailability enhancement. However certain limitations are 
associated with SMEDDS formulations which include in vivo drug precipitation, 
formulation handling issues, limited lymphatic uptake, lack of predictive in vitro tests 
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and oxidation of unsaturated fatty acids. These limitations restrict their potential 
usage. Inclusion of polymers or precipitation inhibitors within lipid based 
formulations help to maintain drug super saturation after dispersion. This thereby, 
improves the bioavailability. 
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CHAPTER- II 
SELF MICRO EMULSIFYING DRUG DELIVERY SYSTEM- REVIEW 
Self Emulsifying Drug Delivery system (SMEDDS) is a new approach 
to improve the solubility of poorly soluble drugs. It can be ideally called as an 
isotropic mixture. Drugs which are lipophilic in nature can be formulated in this 
lipid based drug delivery system. SMEDDS improves solubility thereby 
increases dissolution rate and bioavailability of drugs. Drug, oil, surfactant, 
solvent and co-solvent are the components of SMEDDS. It forms small 
droplets due to agitation. The size of the droplet is 10- 100nm. Absorption of 
drug is improved by small droplets due to its ability to increase the interfacial 
surface area. In this system, the drug is dissolved in oil, solvent or surfactant 
.Co-solvents are used when required. Once it enters into the stomach it forms 
micro emulsion due to mild agitation. Agitation is caused by the digestive 
motility and intestine. SMEDDS is available as different dosage forms such as 
capsules, tablets, suppositories and topical preparations. 
ADVANTAGES OF SMEDDS : 
•  Enhances oral bioavailability. 
• Delivers peptides, protein.  
•  Available in both liquid and solid dosage form. 
•  Poorly water soluble drugs can be used. 
•  Improve patient compliance. 
•  The drug is protected by oil droplets. 
•  Drugs will not be affected by presence of food. 
•  Has reproducible drug absorption profile. 
•  Gives prolonged release due to use of appropriate Polymer. 
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 Limitations Of SMEDDS : 
• Lack of in-vitro models for evaluation. 
•  Dissolution test cannot be completely relied on, because this 
formulation depends on digestion. 
•  It causes GIT irritation due to the excess amount of Surfactant. 
•  Use of co-solvents can destroy the soft gelatin. 
 FACTORS AFFECTING SMEDDS  
• Dose of drug: The drugs which have low solubility at high dose are not 
suitable for SMEDDS. The drugs required to administer at high dose 
should possess good solubility in the components used at least in oil 
phase. 
• Solubility of drug: The drug should be highly soluble which influences 
its bioavailability. The incorporation of surfactants and co-surfactants at 
high concentration can cause risk of precipitation. 
• Polarity of lipid phase: Release of drug is highly influenced by 
polarity of lipid phase. High polarity value increases the rate of release. 
• Droplet size and charge: Smaller the droplet size and larger the 
surface area increases absorption and if the droplet is positively 
charged the drugs can penetrate into the physiological barrier in deep 
leads to improved bioavailability. 
 FORMULATION OF SMEDDS 
The following should be considered in the formulation of SMEDDS. 
• The solubility of the drug in different oil, surfactants and co-solvents 
• The selection of oil, surfactant and co-surfactant based on the solubility 
of the drug 
• Preparation of the phase diagram 
• The preparation of SMEDDS formulation, by dissolving the drug in a 
mixture of oil, surfactant and co-surfactant. 
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COMPONENTS OF SMEDDS:   
          Self micro emulsification has been shown to be specific to  
• The nature of the oil/surfactant pair. 
• The surfactant concentration and oil/surfactant ratio. 
• The temperature at which self emulsification occurs. 
In support of these facts, it has also been demonstrated that only very 
specific pharmaceutical excipient combinations could lead to efficient self 
emulsifying systems. 
Poorly water soluble drugs can be delivered orally by pre-dissolving 
the compounds in appropriate solvent and fill the formulation into capsules. 
The initial rate limiting step of particulate dissolution in the aqueous 
environment within the GI tract can be overcome by this approach. The main 
problem is that the formulation may disperse in the GI tract which produces 
precipitation of drugs in the solution, It occurs mostly with hydrophilic solvents 
(e.g. polyethylene glycol). Occurrence of precipitation on dilution in the GIT 
can be avoided by dissolving the components in lipid vehicle. Water-soluble 
polymer can be used to aid solubility of the drug compound. For example, 
polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG 6000) have been 
used for preparing solid solutions with poorly soluble drugs. Crystallisation of 
the polymer matrix due to thermodynamically stable state is one of the 
problems in this type of formulation that affects the physical stability of the 
product which can be studied by Differential scanning calorimetry or X-ray 
crystallography. SMEDDS are novel approach to enhance the solubility, 
bioavailability and protect the drug from gastric environment which gives 
better systemic absorption of drugs. 
DRUG: 
Lipophilicity and dose of the drug are the main criteria to be considered 
be considered before the development of SMEDDS formulation. Drugs which 
are administered at very high dose are not suitable for SMEDDS unless they 
exhibit extremely good solubility in at least one of the components of 
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SMEDDS. Ideally drug should have low dose, log P> 2 and should not 
possess extensive first pass metabolism. High melting point drugs with log P 
values about 2 are poorly suited to SMEDDS. At the other end of the 
spectrum, lipophilic drugs with log P values greater than 5, are good 
candidates for SMEDDS. 
OILS: 
  The oil represents one of the most important excipients in the self 
emulsifying formulations not only because it can solubilised marked amounts 
of the lipophilic drug or facilitate self emulsification but also and mainly 
because it can increase the fraction of lipophilic drug transported via the 
intestinal lymphatic system, thereby increasing absorption from the GI tract 
depending on the molecular nature of the triglyceride. Both long and medium 
chain triglyceride oils with different degrees of saturation have been used for 
the design of self emulsifying formulations. Furthermore edible oils which 
could represent the logical and preferred lipid excipients choice for the 
development of SMEDDS are not frequently selected due to their poor ability 
to dissolve large amounts of lipophilic drugs. Modified or hydrolyzed vegetable 
oils have been widely used since these excipients form good emulsification 
system with a large number of surfactants approved for oral administration 
and exhibit better drug solubility properties. They offer formulative and 
physiological advantages and their degradation products resemble the natural 
end products of intestinal digestion. Novel semi synthetic medium chain 
derivatives, which can be defined as amphiphilic compounds with surfactant 
properties, are progressively and effectively replacing the regular medium 
chain triglyceride oils in the SMEDDS formulation. 
SURFACTANTS: 
          Several compounds exhibiting surfactant properties may be employed 
for the design of self emulsifying systems, but the choice is limited as very few 
surfactants are orally acceptable. The most widely recommended ones being 
the non-ionic surfactants with a relatively high hydrophilic –lipophilic balance 
(HLB). The most widely recommended ones being the non ionic surfactants 
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with a relatively high HLB value. the commonly used emulsifiers are various 
solid or liquid ethoxylated polyglycolyzed glycerides and polyoxyethylene 20 
oleate (Tween 80). Safety is a major determining factor in choosing a 
surfactant. Emulsifiers of natural origin are preferred since they are 
considered to be safer than the synthetic surfactants. However these 
surfactants have a limited self emulsification capacity. Non-ionic surfactants 
are less toxic than ionic surfactants but they may lead to reversible changes in 
the permeability of the intestinal lumen. Usually the surfactant concentration 
ranges between 30 and 60% w/w in order to form stable SMEDDS. It is very 
important to determine the surfactant concentration properly as large amounts 
of surfactants may cause GI irritation. Surfactants are amphiphilic in nature 
and they can dissolve or solubilized relatively high amounts of hydrophobic 
drug compounds. The lipid mixtures with higher surfactant and co-
surfactant/oil ratios lead to the formation of SMEDDS. (shukla Prachi et al. 
IRJP 2012,3(9) 
CO-SURFACTANTS: 
            Co-surfactants ensures flexibility of the interfacial layer, i.e. it reduces 
the interfacial tension to a negative value. Co-surfactants form a flexible 
interfacial film in order to acquire different curvatures required to form micro 
emulsions over a wide range of compositions. Medium chain length alcohols 
(C3-C8) are commonly employed as co-surfactants. Organic solvents such 
as, ethanol, propylene glycol, and poly ethylene glycol are suitable for oral 
delivery, and they enable the dissolution of  large quantities of either the 
hydrophilic surfactant or the drug in the lipid base. On the other hand alcohols 
have the disadvantage of evaporating into the shells of the soft gelatin, or 
hard, sealed gelatin capsules in conventional SMEDDS leading to drug 
precipitation. Thus, alcohol free formulations have been designed, but their 
lipophilic drug dissolution ability may be limited. 
MECHANISM OF SELF-EMULSIFICATION: 
Self emulsification process occurs, when the entropy changes. The 
energy required to increase the surface area of the dispersion is smaller than 
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the dispersion. The free energy of conventional emulsion formation is a direct 
function of the energy required to create a new surface between the two 
phases and can be described by the equation 
δG=ΣNiπri2σ 
Where, 
      δG- is the free energy associated with the process (ignoring the free 
energy of mixing) 
      N- is the number of droplets of radius r 
      σ is the interfacial energy with time 
The two phases of the emulsion will tend to separate, in order to reduce 
the interfacial area and subsequently, the free energy of the system. Therefore, 
the emulsions resulting from aqueous dilution are stabilized by conventional 
emulsifying agents, which form a monolayer around the emulsion droplets and 
hence, reduce the interfacial energy, as well as providing a barrier to 
coalescence. 
In case of self-emulsifying system, the free energy required to form the 
emulsion is either very low or positive or negative then, the emulsion process 
occurs spontaneously. Emulsification requires very little input energy, which 
involves destabilization through contraction of local interfacial regions. For 
emulsification to occur, it is necessary for the interfacial structure to have no 
resistance to surface shearing. 
In earlier work it was suggested that the case of emulsification could be 
associated with the ease by which water penetrates into the various liquid 
crystal or phases get formed on the surface of the droplet. The addition of a 
binary mixture (oil/non-ionic surfactant) to the water  results in the interface 
formation between the oil and aqueous continuous phases, followed by the 
solubilisation of water within the oil phase owing to aqueous penetration 
through the interface, which occurs until the solubilisation limit is reached 
close to the interface. Further aqueous penetration will result in the formation 
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of the dispersed liquid crystalline phase. 
As the aqueous penetration proceeds, eventually all materials close to 
the interface will be liquid crystal, the actual amount depending on the 
surfactant concentration in the binary mixture once formed, rapid penetration 
of water into the aqueous cores, aided by the gentle agitation of the self 
emulsification process causes interface disruption and droplet formation. A 
combination of particle size analysis and low frequency dielectric 
spectroscopy was used to examine self-emulsifying properties of a series of 
Imwitor 742 (a mixture of mono and diglycerides of Caprylic acids/Tween 80) 
systems, which provided evidence that the formation of the emulsion may be 
associated with liquid crystal formation, although the relationship was clearly 
complex. 
  The presence of the drug may alter the emulsion characteristics, 
possibly by interacting with the liquid crystal phase. The droplet structure can 
pass from a reversed spherical droplet to a reversed rod-shaped droplet, 
hexagonal phase, lamellar phase, cubic phase or other structures until, after 
appropriate dilution, a spherical droplet will be formed again. 
DOSAGE FORM DEVELOPMENT OF S-SMEDDS: 
                 Various dosage forms of S-SMEDDS are 
•  Dry emulsions 
• Self- emulsifying capsules 
• Self –emulsifying sustained/controlled release tablets 
• Self-emulsifying sustained/controlled pellets 
• Self-emulsifying solid dispersions 
• Self-emulsifying beads 
• Self-emulsifying sustained release microspheres 
• Self –emulsifying nanoparticles 
• Self-emulsifying suppositories 
• Self-emulsifying implant. 
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Self-emulsifying tablets: 
Incorporation of lipid formulation into a solid dosage form combines the 
advantages of lipid-based drug delivery systems with those of solid dosage 
forms. Attama (2003) formulated a solid self-emulsifying formulation using 
goat fat and tween for the delivery of diclofenac. Fatty material was melted 
and mixed with surfactant and the drug incorporated into this mixture. This 
wet mass was poured into plastic molds and cooled to form a tablet. During 
the processing of this formulation it was observed that agitation during 
fabrication of tablets reduced the liquification time, resulting in faster 
emulsification. These results demonstrated that different formulation ratios 
possess varying dissolution profiles at constant speed/agitation, and the 
optimized formulation showed good release profiles with acceptable tablet 
properties. 
Nazzal and Khan (2006), evaluated the effect of some parameters 
(colloidal silicates-X1, magnesium stearate mixing time X2, and compression 
force X3) on coenzyme Q10 (CoQ10) dissolution from tablets of eutectic 
based SMEFs. The optimized conditions (X1= 1.06%, X2 = 2 min, X3 = 1670 
kg) were achieved by a face centred cubic design. 
In order to significantly reduce the amount of solidifying excipients 
required for transformation of SEFs into solid dosage forms, gelled SEFs 
have been developed by Patil (2004). In this study, colloidal silicon dioxide 
(Aerosil 200) was selected as a gelling agent for the oil-based systems. 
Colloidal silicon dio- xide served a dual purpose: (i) – reducing the amount of 
solidifying excipients required; and (ii) aiding in reducing drug release. 
In a clinical study, it was found that SE tablets may be of use in reducing 
adverse effects (Schwarz, 2003). The incorporation of indomethacin (or other 
hydrophobic NSAIDs) in SE tablets was found to increase the penetration 
efficacy of the drug through the GI mucosal membranes, potentially reducing 
GI bleeding. The SEF in this study composed of glycerol monolaurate and 
Tyloxapol TM (a copolymer of alkyl phenol and formaldehyde). The tablets 
consistently maintained a higher active ingredient concentration in blood 
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plasma over the same time period compared with a non-emulsifying tablet. 
Self-emulsifying powder formulation (SE powder formulation) 
             Arida et al. (2007) formulated an SE powder formulation in order to 
enhance the dissolution and absorption of the poorly water-soluble drug 
griseofulvin. Capmul GMO-50, poloxamer and myvacet were used as 
surfactants and co-surfactants. A significant enhancement in dissolution 
(without ultra-micronisation) and bioavailability of griseofulvin was observed. 
Balakrishnan et al. (2009) developed a novel solid SEF of dexibuprofen 
using spray drying. Aerosil 200 was used as an inert solid carrier. Both in-vitro 
and in-vivo studies were carried out. The optimization of the SEF 
composition was carried out by assessing solubility, prepa- ration of phase 
diagram, particle size analysis, drug release studies etc. The study showed 
that Labrafil M 1944 CS, Labrafil M 2125, Labrasol, Capryol 90 and 
Lauroglycol FCC could enhance the solubility of CoQ10 and provide the 
desired drug loading. 
Self-emulsifying pellets (SE pellets) 
Oral pellets are known to overcome the poor and variable GIT 
absorption of drugs and have shown the ability to reduce or eliminate the 
influence of food on bioavailability. Thus, it appears highly appealing to 
combine the advantages of pellets with those of SETs by formulating SE 
pellets. Kang et al. (2004) as part of their study to develop a self-emulsifying 
drug delivery system, have reported considerable differences in the solubility 
of simvastatin in a range of surfactants. The authors suggest that the 
properties of surfactants need to be considered when selecting them for the 
formulation of SE pellets. 
Franceschinis et al. (2005) developed a new method for preparing self-
emulsifying pellets by wet granulation consisting of a binder solution containing 
an oil (mono and diglycerides), polysorbate 80 and nimesulide as a model 
drug. The oil surfactant mixture was added to water to obtain binder solution. 
The prepared binder solutions were sprayed onto the granules (prepared from 
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microcrystalline cellulose and lactose) to give pellets. In vivo studies indicated 
significantly higher bioavailability with the prepared pellets in comparison to 
the corresponding emulsions. 
Tuleu (2004) conducted a comparative bioavailability study of 
progesterone from SE pellet formulation, SE solution, capsule and an 
aqueous suspension in dogs. Complete drug release was seen within 30 min 
of capsule administration and within 5 min of administration of the self-
emulsifying system. However, in the case of aqueous suspension the drug 
release was very low (~50% of the dose in 60 min). Plasma drug 
concentration was significantly higher when the drug was orally administered 
from self-emulsifying pellets and self-emulsifying solution when compared to 
aqueous suspension at the same dose. 
Abdalla and Mader (2007) prepared three self- emulsifying pellet 
formulations by melting cithrol GMS (mono and diglycerides) and solutol HS 
15. To this molten blend, the drug (diazepam) and dry microcrystalline 
cellulose (MCC) were added to obtain a suitable mass for extrusion. A dye 
was incorporated for assessment of self-emulsification and spin probe was 
added to assess the release kinetics and microenvironment of pellets. The 
results from the release study, with higher load of diazepam and lower volume 
of the dissolution media, indicated that the formulation was able to create and 
maintain a state of supersaturation for the poorly water-soluble diazepam. 
Nearly 90% of the drug was released within an hour while only 55% was 
released from the GMS/MCC pellets. 
Wang et al. (2010) demonstrated that the extrusion/ spheronization 
technique is a large-scale production method for preparing solid SE pellets 
from the liquid SEF to improve oral absorption. SE pellets of a hydrophobic 
drug (nitrendipine) were prepared. Formulation stability and solubilisation 
capacity were noted. The system was optimized on the basis of equilibrium 
solubility, pseudo- ternary phase diagram and supersaturation studies. The 
liquid SEFs were solidified using adsorbents (porous silicon dioxide), MCC 
and lactose to form fine flowable powder. Crospovidone was added to the 
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formulation. The AUC of nitrendipine from the SE pellets was two-fold 
greater than the conventional tablets and was comparable with the liquid 
SEFs. 
Controlled release self-emulsifying pellets 
             Serratoni and Newton (2007) observed that the release of methyl 
paraben (MP) and propyl parabens (PP) from pellet formulations could be 
controlled by incorporating them into self-emulsifying systems containing 
water soluble plasticiser and talc. Oil and surfactant were mixed and added 
to the damp mass of MCC and lactose mono- hydrate. Extrusion 
spheronization of the wet mass was carried out. The pellets obtained were 
initially coated with ethyl cellulose and subsequently with an aqueous solution 
of hydroxy propylmethyl cellulose in a fluid bed coater. Results obtained from 
the in vitro study revealed that the presence of self-emulsifying system 
enhanced drug release of MP and PP while the film coating considerably 
reduced the drug release from pellets. 
Iosio et al. (2008) prepared two types of pellets containing vinpocetine 
(model insoluble drug) where Type I pellets contained a self-emulsifying 
system internally and an inert matrix externally, whereas Type II contained 
an inert matrix internally and a self-emulsifying system externally. 
Formulations were prepared in two steps. In the first step, the oil-surfactant 
mixture was added to water to form self-emulsifying systems whereas in the 
next stage this mixture was loaded onto MCC and lactose to form extrusion-
spheronization mass for pellets. Results indicated that Type I pellets released 
90% of vinpocetine within 30 min while the same quantity was released within 
20 min from Type II pellets. The physical mixture of the excipients with drug 
was able to release around 25% of the drug in 60 min. Although both types of 
pellets demonstrated adequate morphological and technological 
characteristics, type II pellets showed better drug solubility and in vivo 
bioavailability. The above investigations suggest that a solid dosage form 
containing a self-emulsifying system is a promising approach for the 
formulation of drug compounds with poor aqueous solubility. 
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Self-emulsifying beads (SE beads) 
Self-emulsifying beads can be formulated as a solid dosage form using 
smaller amounts of different excipients. Patil and Paradkar formulated an 
isotropic formulation of loratadine consisting of Captex 200, Cremophore EL 
and Capmul MCM. The SE mixture was loaded onto poly propylene beads 
(PPB) using the solvent evaporation method. Formulations were optimized for 
loading efficiency and in vitro drug release by evaluating their geometrical 
features such as bead size and pore architecture. Results indicated that the 
poly propylene beads are potential carriers for solidification of SE mixture, 
with sufficiently high SE mixture to PPB ratios for the solid form. The results 
indicated that self- emulsifying beads can be formulated as a solid dosage 
form with a minimal amount of solidifying agents. 
Self-emulsifying sustained-release microspheres 
You et al. (2006) prepared solid SE sustained-release microspheres of 
zedoary turmeric oil (oil phase) using the quasi-emulsion-solvent-diffusion 
method involving spherical crystallization. The release behaviour of zedoary 
turmeric oil from the formulation was found to be dependent upon the hydroxyl 
propyl methylcellulose acetate succinate to Aerosil 200 ratio. The plasma 
concentration time profiles after oral administration in rabbits showed a 
bioavailability of 135.6% compared with the conventional liquid SEFs. 
Self-emulsifying implants (SE implants) 
Research into SE implants has greatly increased the use and application 
of solid self-emulsifying formulation (S-SEF). Carmustine (BCNU) is a 
chemotherapeutic agent used to treat malignant brain tumours. However, its 
effectiveness is hindered by its short half life. In order to enhance its 
stability, the SEF of carmustine was formulated using tributyrin, 
Cremophor RH 40 (polyoxyl 40 hydrogenated castor oil) and Labrafil 1944 
(polyglycolyzed glyceride). The self-emulsified BCNU was fabricated into 
wafers with a flat and smooth sur- face by compression moulding. The 
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release profile was compared with a wafer implant fabricated using poly (d,   
l-lactide-co-glycolide) acetic acid. It was found that SEF increased the in vitro 
half-life of BCNU to 130 min compared with 45 min with intact BCNU. The in 
vitro release of BCNU from self-emulsifying PLGA wafers was prolonged up to 
7 days and was found to have higher in vitro anti-tumor activity (Chae et al., 
2005). 
Self-microemulsifying formulations 
Self-micro emulsifying formulations (SMEFs) have attracted great 
attention recently. In an attempt to combine the advantages of SMEFs with 
those of solid dosage forms and overcome the shortcomings of liquid 
formulations, increasing attention has been focused on solid self-(micro) 
emulsifying formulations. The thermotropic stability of SMEFs and their high 
drug loading efficiency make them a promising system for low aqueous soluble 
drugs (Jannin et al., 2007). SMEFs are usually placed in soft gelatin 
capsules, but can also be transformed into granules, pel- lets, powders for 
dry filled capsules or tablet preparations (Nazzal, Khan, 2006; Serratoni, 
Newton, 2007; Abdalla et al., 2008; Tan et al., 2009). The commercial 
success of the SMEF, Neoral® drew greater attention to the development of 
SMEFs. Many poorly water-soluble drugs such as acyclovir, atorvastatin, and 
fenofibrate have been reported to offer improved oral bioavailability by SMEFs 
(Wang et al., 2006; Shen, Zhong, 2006; Patel, Vavia, 2007). 
Postolache et al. (2002) compared the bioavailability of two cyclosporine 
capsule products with different pharmaceutical formulations. Results showed  
that the test cyclosporine non-SMEFs formulation was not bioequivalent to the 
cyclosporine SMEFs formulation due to a statistically significantly lower 
absorption rate. These authors demonstrated that the non-self 
microemulsifying capsules are not totally interchangeable with the self 
microemulsifying capsules unless validated clinical and laboratory conversion 
protocols for each kind of organ transplantation are enforced. 
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Catarzi et al. (2008) reported the comparative impact of Transcutol and 
Neusilin US2 on SMEFs. Results showed that the Neusilin- formulation 
resulted in hard tablets with a low tablet weight. However, Neusilin® tablets 
had similar disintegration times compare to Aeroperl (Evonik Degussa). The 
dissolution profile obtained from the tablets showed improved profile when 
compared to Glyburide alone. Zvonar et al. (2010) suggested that, SMEFs 
possessing a composition similar to microcapsules with Ca-pectinate shell 
and a drug loaded SMEFs as the core phase, would be a potential 
approach for enhancing low permeability and solubility of BCS class II 
drugs. 
Self nanoemulsifying formulations (SNEFs) 
          The classical lipid nanoparticles that have been proposed for drug 
delivery are composed of solid lipids. A distinct advantage of SNEFs over 
polymeric nanoparticles is that the lipid matrix is made from physiologically 
tolerated lipid components, which decreases potential acute and chronic 
toxicity. 
Nazzal et al. (2002) developed a SNEF based on the eutectic properties 
of ubiquinone (CoQ10) and also studied the progress of emulsion formation 
and drug release mechanisms by turbidimetry and droplet size analysis. 
Results obtained from study revealed that eutectic-based semisolid SEFs 
can overcome the drawbacks of the traditional emulsified systems such as 
low solubility and irreversible precipitation of the active drug in the vehicle 
with time. 
Cyclosporine lipid nanoparticles (lipospheres) consisting of 
phospholipids, Span 80, Tween 80, Tricaprin, and Cremophor RH 40 were 
prepared (Bekerman et al., 2004). The CsA dispersion systems prepared had a 
particle size ranging from 25 nm to 400 nm. Particles with a size of 25 nm 
showed maximum oral bioavailability. 
In a study by Nepal et al.(2010), the surfactant–co-surfactant blend 
(Witepsol H35 and Solutol HS15) at a ratio of 1:4 led to sufficient reduction in 
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free energy of the system to resist thermodynamic instability of the nano-
emulsion as well as providing a sufficient mechanical barrier to coalescence 
oil droplets. 
Koynova et al. (2010) suggested the use of nano sized self-emulsifying 
lipid vesicles as carriers for the inclusion of lipophilic dietary supplements. 
These were proposed as good alternatives to liposomal preparations which 
pose problems in stability, sterilization, and non- reproducibility between 
batches. 
Supersaturable self-emulsifying formulation 
Supersaturation represents a potent technique for enhancing absorption 
by generating and maintaining a supersaturated state in the intestine. Such 
formulations contain both a reduced amount of surfactant(s) and a 
polymeric precipitation inhibitor (e.g., water-soluble cellulosic polymers, 
such as HPMC). These maintain a supersaturated state of the drug in the body. 
As the literature suggested, directly supersaturating a system with a drug 
during manufacture adds to the risk of recrystallization of the product. Various 
ways of inhibiting recrystallization have been identified. Thermodynamic 
“freezing” inside a polymer is one such option. Under storage conditions, the 
drug is mobilized by thermodynamic changes in the poly- meric structure. To 
avoid risk of direct supersaturation, several strategies can be employed, for 
example: 
• Evaporation of a solvent from the system 
• Activation of thermodynamically “frozen” drug- supersaturated islands 
by hydration. 
However, attaining full knowledge of these processes, especially in a 
multi- component formulation, requires extensive research. Recently, Gao et al. 
(2008) investigated the mechanism responsible for the enhanced intestinal 
absorption of hydrophobic drugs from supersaturable SEFs containing 
HPMC. This effect could be attributed to enhanced permeation of drug to the 
enterocyte brush border region through the aqueous pathway by mimicking, or 
equilibrating with, the bile acid /bile acid mixed micelle pathway. 
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Techniques used to produce solid SMEDDS: 
     Various techniques have been employed to produce SMEDDS. 
• Spray drying: 
 In this method, all the excipients are mixed together. The formulation 
is atomized into small droplets. The droplets are introduced into the drying 
chamber the temperature and airflow is maintained as per required. Further it 
can be prepared as capsules /tablets. 
• Adsorption onto solid carrier 
In this method the liquids are mixed with the excipients. The powdered 
mixture is filled into capsules or it can be formulated as tablets. The benefit of 
this technique is it ensures content uniformity. 
• Melt agglomeration: 
Powder agglomeration can be obtained by melt granulation. It is 
obtained by using binder which melts at low temperature. 
• Melt extrusion: 
It is a solvent free method. In this process, the raw material which has 
plastic properties converts into a product with uniform density and shape; it is 
obtained by forcing the raw material into a die. This process is carried out 
under controlled pressure, temperature and proper flow of product. The 
advantage of this method is high drug loading and content uniformity. 
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Limitations of SMEDDS: 
 Although SMEDDS formulations has several advantages, there are 
certain limitations associated with this system  
1. Drug precipitation on dilution: 
 Diluted SMEDDS undergo precipitation of drug in gastro intestinal fluid. 
A common requirement for the lipid formulation is that they should be able to 
keep the drug in the solubilised form in the gastrointestinal tract. Precipitation 
of the drug from the system nullifies the advantage offered by the lipid based 
formulation system. The precipitation tendency of the drug on dilution is 
higher due to the dilution effect of the hydrophilic solvent. It thereby requires 
incorporation of polymers to minimize drug precipitation. 
2. Encapsulation in soft gelatin capsules: 
        Most of the marketed SMEDDS formulations are available as soft 
gelatin capsule. However gelatin capsules are associated with few 
drawbacks. Manufacturing cost, transmissible spongiform encephalopathy 
(TSE) and consumer preference are the few issues associated with animal 
gelatin. Volatile co-solvents in self-micro emulsifying formulations are known 
to migrate into the shells of soft or hard gelatin capsules, resulting in the 
precipitation of the lipophilic drugs. These problem drive the market 
requirement to find substitute for soft gelatin capsules. The current alternative 
material of choice, to animal gelatin capsules are HPMC capsules. The HPMC 
capsule shell has been explored as an alternative approach for encapsulating 
supersaturable SMEDDS formulation. 
3. Storage and handling:  
 Liquid SMEDDS exhibit problems in handling, storage and stability. 
Thus, formulating solid SMEDDS seems to be a logical solution to address 
these problems. 
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4. Limited targeting to lymphatics: 
 Targeting lymphatics confers two primary advantages over 
conventional absorption via the portal blood. First, transport through the 
intestinal lymph avoids pre-systemic hepatic metabolism and thereby 
enhances the concentration of orally administered drugs reaching the 
systemic circulation. Second, site-specific hepatic metabolism and thereby 
enhances the concentration of orally administered drugs reaching the 
systemic circulation. Second, site-specific drug delivery to lymphatic organs 
could be achieved. Normally high triglyceride solubility and high log P is 
required for lymphatic transport. However, the amount of drug transported into 
lymphatics is variable from drug to drug. Hence, lipophilicity and triglyceride 
solubility of drug in correlation with lymphatic transport needs to be completely 
understood and a more adequate predictive models is required 
5. Lack of good in vitro models: 
 Another obstacle in the development of SMEDDS and other lipid-based 
formulations is the lack of good predicative in vitro models for the assessment 
of the formulations. Traditional dissolution methods do not work, as these 
formulations potentially are dependent on digestion of lipid in the gut, prior to 
release of the drug. Although to mimic this, an in vitro model simulating the 
digestive processes of the duodenum has been developed. This in vitro model 
needs further refinement and validation before its strength can be evaluated. 
Further development can be based on in vitro- in vivo correlations and 
therefore, different prototype lipid based formulations need to be developed 
and evaluated in vivo in a suitable animal model. 
6. Oxidation and polymorphism of the lipids used in formulation 
SMEDS: 
 Lipid excipients containing unsaturated fatty acids and its derivatives 
are prone to lipid oxidation. This requires inclusion of lipid soluble antioxidant 
in capsule formation. Polymorphism associated with thermo-softening lipid 
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excipients requires specific process control in their application, in order to 
minimize polymorphic changes of the excipient matrix.   
Handling and storage issues with liquid SMEDDS 
 SMEDDS are normally viscous liquids that are administered in hard or 
soft gelatin capsule. Lipid formulation may leach into and interact with the 
capsule shells. This may cause brittleness or softness of the capsule shell, 
leakage of the content and precipitation of the drug or excipients, especially at 
lower temperatures. To address these problems, several attempts have been 
made to transform liquid SMEDDS into solid SMEDDS dosage forms. These 
approaches combine the advantages of SMEDDS with those of solid dosage 
forms while overcoming the disadvantages of liquid SMEDDS. Formulating 
solid SMEDDS combine the advantages of SMEDDS with those of solid 
dosage forms, ie. Low production cost, convenience of process control, high 
stability, reproducibility, better patient compliance. Thus, the presentation of 
liquid SMEDDS in a solid dosage form provides more stable and robust 
dosage form with lower manufacturing costs. 
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CHAPTER - III 
 REVIEW OF LITERATURE  
 
Tarkeshwar Prasad Shukla et al., (2017), were formulated 
Acetazolamide SMEDDS and evaluated. The optimized formula was selected 
to have the smallest mean particle size and the highest absolute Zeta 
potential, which should yield the formation of a stable emulsion. The in vitro 
dissolution indicated a significant improvement in Acetazolamide release 
characteristics. The preformulation study of drug was carried out initially in 
terms of physical appearance, melting point, solubility study, λ max 
determination (wavelength at maximum absorbance) solubility study, and 
results directed for the further course of formulation. The formulations were 
prepared with different ratios of oil, surfactant and co-surfactant. The 
SMEDDS were prepared and are evaluated in terms of droplet size, drug 
release etc.  The system consist of Arachis Oil, Lutrol F-68, Triacetin & 
Propylene Glycol as oil phase, surfactant and co-surfactant respectively.NIP 
C1 & NIP C8 selected as optimized batches showed promising results. Zeta 
potential of NIP C8 indicates good stability. NIP C1 & NIP C8 showed Poly 
dispersity index below 0.3 which shows good uniformity in the droplet size 
distribution. Time of emulsification was under grade A (visual assessment 
criteria), thermodynamic stability testing & accelerated stability study was 
performed for optimized batches. In this study SMEDDS is a promising 
approach to improve the solubility, dissolution rate and bioavailability of 
Acetazolamide. 
Yuxia Zhang et al., (2017), developed and evaluated colon-specific 
capsule with alginate beads containing a self-micro emulsifying drug delivery 
system (SMEDDS). The SMEDDS technique was used to improve the 
solubility of curcumin (Cur). After encapsulating the Curcumin -loaded 
SMEDDS, the alginate beads were placed inside an impermeable capsule 
body. A konjac glucomannan/lactose/hydroxypropyl methylcellulose (KG/Lac/ 
HPMC) plug tablet was then prepared and placed in the mouth of the capsule. 
The capsule demonstrated a pulsatile drug-release profile with a specific lag 
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time and subsequent sustained-release phase. The lag time was modified by 
changing the type of HPMC and the ratio of KG/Lac/HPMC. In addition, 0.5% 
b-mannase solution and 5% rat cecal solution were used to simulate the colon 
fluid, significantly decreasing the lag time of the capsule. The results show 
that the capsule has potential for use in colon-specific drug delivery and 
exhibits a sustained-release characteristic. 
Pallavi Patharkar et al., (2016), were formulated and evaluated solid 
self emulsifying drug delivery system of Olmesartan Medoxomil by adsorption 
to solid carrier technique to improve the oral bioavailability of drug. The 
solubility of OLM was deterimiced in various vehicles kike oils, surfactants and 
co-surfactant. Pseudoternary phase diagrams were constructed to identify the 
efficient self emulsifying region. The system consists of Olmesartan, Acrysol 
k-150, Labrasol, Transcutol P as a drug, oil, surfactant and co-surfactant. The 
optimized liquid SMEDDS was transformed into a free flowing powder using 
Avicel or Aerosil 200 as the adsorbent. Prepared formulations were tested for 
microemulsifying properties and the resultant micro emulsions were evaluated 
for robustness to dilution, assessment of efficiency of self emulsification, 
emulsification time, turbidity measurement, viscosity, drug content and in-vitro 
dissolution. The physical state of the drug in solid self micro emulsifying 
powder was revealed by Differential Scanning Calorimetric and X-ray powder 
diffraction studies which indicated the presence of the drug was enhanced 
significantly from the SMEDDS formulations as compared to pure drug. 
Karunakara reddy et al., (2016), formulated self micro emulsifying drug 
delivery system of atazanavir and evaluated for their properties and invitro 
release studies. Solubility of atazanavir was determined in various oils, 
surfactants, and co-surfactants. Pseudo ternary phase diagrams were 
constructed to determine the concentration range of oils, surfactant, and co-
surfactant. The optimized formulation consists of castor oil as an oil phase, 
kolliphore RH as a surfactant and PEG 400 as a co-surfactant. The liquid 
SMEDDS formulations were prepared and evaluated for zeta potential, 
polydispersity index, % transmittance, drug content and invitro dissolution 
studies. Then the optimized liquid formulation ( drug content -97.76%; drug 
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release-95.42%) was converted into free flowing powder using Neusilin US2. 
Then the solid SMEDDS were evaluated for drug content (97.89%). The solid 
SMEDDS showed better  drug release than the pure drug of Atazanavir. So 
the SMEDDS approach may be useful for the enhancement of solubility of 
poorly water soluble compounds. 
Xiaolin Bi et al., (2016), were developed a solid self-microemulsifying 
drug delivery system (S-SMEDDS to load the various active constituents of 
salvia (dried root of Salvia miltiorrhiza) which contains both lipophilic (e.g., 
tanshinone IIA, tanshinone I, cryptotanshinone and dihydrotanshinone I) and 
hydrophilic (e.g., danshensu and salvianolic acid B) constituents, into a single 
drug delivery system and improve their oral bioavailability. A prototype 
SMEDDS was designed using solubility studies and phase diagram 
construction, and characterized by self-emulsification performance, stability, 
morphology, droplet size, polydispersity index and zeta potential. 
Furthermore, the S-SMEDDS was prepared by dispersing liquid SMEDDS 
containing liposoluble extract into a solution containing aqueous extract and 
hydrophilic polymer, and then freeze-drying. In vitro release of tanshinone IIA, 
salvianolic acid B, cryptotanshinone and danshensu from the S-SMEDDS was 
examined; showing approximately 60%–80% of each active component was 
released from the S-SMEDDS in vitro within 20 min. In vivo bioavailability of 
these four constituents indicated that the S-SMEDDS showed superior in vivo 
oral absorption to a drug suspension after oral administration in rats. It can be 
concluded that the novel S-SMEDDS developed in this study increased the 
dissolution rate and improved the oral bioavailability of both lipophilic and 
hydrophilic constituents of salvia. Thus, the S-SMEDDS can be regarded as a 
promising new method by which to deliver salvia extract, and potentially other 
multicomponent drugs, by the oral route. 
 Nilesh mahadeo et al., (2016), were developed Liquid self micro 
emulsifying drug delivery system (L-SMEDDS) of Cefpodoxime proxetil (CFP) 
a poorly absorbable, high dose antibiotic having pH dependant solubility to 
overcome the problems associated with oral delivery. Solubility of CFP in 
various oils was determined to select the key components of SMEDDS. 
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Surfactants and co surfactants were screened and selected on the basis of 
their % transmittance. In this formulation Capmul MCM (650 mg of drug/1g of 
oil), Cremophore RH 40 (% T-90.12 %), Labrafil 2125 CS (% T-99.03%) were 
used as an oil, surfactant and co-surfactant respectively. Neusilin US2 was 
used as an adsorbing agent to convert optimized L-SMEDDS to Solid Self 
micro emulsifying drug delivery system (S-SMEDDS), which were then filled in 
hard gelatin capsule and evaluated further. The optimized L-SMEDDS shows 
Globule size 30-35 nm, Zeta potential -10 to -11 (negative ZETA POTENTIAL 
due to the presence of fatty acids in the structure of the excipients), Drug 
content 99.24±0.52 %. The S-SMEDDS shows acceptable flow properties, 
and Particle size of 33.40 nm, Polydispersibility index of 0.125, Zeta potential 
of -11.5 mv, Drug content of 98.32±0.14%. SEM studies showed that there is 
loss of crystalline structure of drug has been converted into amorphous state 
i.e completely solubilised in oil phase of L-SMEDDS and adsorbed on Neusilin 
US2 surface. FTIR studies confirmed that there is no drug- excipient 
interaction. 
Bhalekar MR et al., (2016), formulated self micro emulsifying drug 
delivery system of Darunavir, an anti retroviral protease inhibitor to increase 
its solubility and bioavailability. The SMEDDS system compromising of 
Imwitor 988 as oil phase. Tween 20 and span 20 as binary surfactant system 
were optimized with respect to drug solubilization, particle size, zeta potential, 
dispersibility, optical clarity cloud point, in-vitro release and thermodynamic 
stability.  SMEDDS system containing Imwitor 988 920%) and surfactant mix 
(Smix) (80%) showed maximum drug solubility with least particle size. The ex-
vivo lymphatic uptake studies of Darunavir SMEDDS in presence of lymphatic 
uptake blocker showed 36. 69% drug permeation which increased to 64. 245 
in absences of lymphatic blocker, indicating the drug transport by lymphatic 
path. Cmax of Darunavir SMEDDS was higher than that of the marketed tablet. 
Pluronic f68 treated rats show lesser plasma concentration as compared to 
those administered with SMEDDS. The results suggest that SMEDDS is a 
promising drug delivery system to improve solubility and lymphatic transport 
of anti-HIV drug Darunavir. 
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Divya G. Shereker et al., (2016), were developed and evaluated Self-
micro emulsifying drug delivery system (SMEDDS) of  Ketoprofen, a widely 
prescribed analgesic drug which belongs to BCS class II and exhibit low and 
variable oral bioavailability due to its poor aqueous solubility. Solubility study, 
emulsification ability, ternary phase diagram and central composite design 
(CCD) were used as primary tools to select the components of the system 
and optimize the composition of liquid Ketoprofen SMEDDS. The globule size 
of optimized liquid SMEDDS was 105.08±5.16nm, zeta potential -4.23mV and 
polydispersity index 0.097, % Transmittance 98.45% and self emulsification 
time 28 sec. Optimized formulation F3 containing Oleic acid (10%), Tween 80 
(30%) and Propylene glycol (60%) was adsorbed onto inert solid carrier 
Aerosil 200 in 1:1 ratio to form dry, free flowing powder. The liquid crystal 
phase viscosity increased significantly with increasing amount of aerosil 200 
which in turn increase average globule size of solid SMEDDS 
(303.69±0.933nm) and slower the drug release. S-SMEDDS also 
characterized for DSC, XRD, SEM etc. The in vitro dissolution study indicates 
improved dissolution characteristics with higher percent drug release for solid 
SMEDDS (89.78%) compared to marketed preparation (81.26%) and pure 
drug (71.32%). In conclusion, S-SMEDDS for Ketoprofen holds promise to be 
developed as potential system for improved oral delivery. 
Madhavi K et al., (2016), formulate solid self emulsifying drug delivery 
systems in order to improve the solubility of the highly lipophilic 
antihypertensive drug ramipril. The system was formulated by homogeneously 
mixing oils, surfactants and co-surfactants along with the drug component. 
Based on solubility studies Capmul PG8 NF, Gelucire 44/14 and Transcutol P 
were selected as oil, surfactant co-surfactant respectively in order to prepare 
liquid SMEDDS. Nine different liquid SMEDDS formulations were prepared 
and subjected to various evaluation tests in order to obtain optimized L-
SMEDDS. Out of 9 different formulations S9 formulation was optimized as it 
formed thermodynamically stable emulsion without any drug precipitation and 
phase separation on storage and also showed least globule size (22.56 nm). 
The optimized formulation was loaded onto inert carrier (Sylysia FCP 350) to 
obtain S-SMEDDS, which shows acceptable flow properties. they were further 
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processed for solid state characterization such as XRD, DSC and SEM and 
the results confirmed the transformation of native crystalline nature of drug to 
an amorphous state. FTIR studies also confirmed no drug-excipient 
interaction. S-SMEDDS showed improved invitro dissolution behavior of 
Ramipril over that of pure drug. 
Nilesh khutle et al., (2015), developed Self micro emulsifying drug 
delivery system of Pravastatin sodium (BCS Class III drug with high aqueous 
solubility and low permeability characteristics. The drug shows low absolute 
biovailability (approximately 17%) due to decreased permeability and high first 
pass extraction. So the study was designed to enhance the permeability 
characteristics of hydrophilic drugs and to protect them from hostile 
environment of gut. The solubility of Pravastatin sodium was determined to 
identify the oil phase of SMEDDS. Various surfactants and co-surfactants 
were screened for their ability to emulsify the selected oil. Pseudetenary 
phase diagrams were constructed to identify the efficient self-emulsifying 
region. The SMEDDS formulation was optimized by freeze thaw cycles, 
robustness to dilution and droplet size and zeta potential tests. The optimized 
L-SMEDDS formulation containing Pravastatin -10 mg, Capmul -100 mg, 
Cremophore RH 40 -66.66mg and Labrafil M 2125-33.33 mg was further 
evaluated by in-vitro and ex-vivo release studies. L-SMEDDS was further 
converted into T-SMEDDS by “Liquid loading technique”. T-SMEDDS of 
Pravastatin contained Neusilin, crosspovidone, magnesium stearate and L-
SMEDDS loaded onto it. The results from both L-SMEDDS and T-SMEDDS 
suggest the potential use of SMEDDS to improve GI instability and intestinal 
permeability of BCS class III drug pravastatin 
Kanav midha et al., (2015,) were formulate dispersible self 
microemulsifying (SMEDDS) tablet of atorvastatin for promoting its solubility 
and its oral bioavailability. The liquid SMEDDS were prepared by water 
titration method using oleic acid, Tween 80, and PEG 400 as oil, surfactant, 
and co-surfactant respectively. Then the L-SMEDDS were converted into solid 
SMEDDS by adsorption on solid carriers (Neusilin US2). The S-SMEDDS 
were blended with sodium starch glycolate (disintegrant) and tablet  excipients 
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and compressed into tablets that were dispersible and self micro emulsifying 
in nature. All these formulations were assessed for various physicochemical 
parameters viz. weight variation, hardness, friability, disintegration test. Invitro 
studies of pure drug, SMEDDS, S-SMEDDS and dispersible SMEDDS tablets 
were carried out. Pure drug released only 29.84±0.16% up to 60 minutes and 
all the SMEDDS formulation released 100% of drug in comparatively lesser 
time. The optimized formulation containing 30% of oleic acid, 65% of tween 
80 and 5% co-surfactant show the best results in in vitro studies. And FB1 
(tablet) was considered to e the best since it release 100% drug in 35 mints 
and also has advantages over SMEDDS and S-SMEDDS in tms of stability 
and patient compliance. 
Nilesh S. Kulkarni et al., (2015), developed rosuvastatin calcium-
loaded self-nanoemulsifying powder for improved oral delivery of the drug. 
Solubility study was carried out in different oils, surfactants and co-
surfactants. Based on the solubility study, liquid formulations were prepared 
using LAS/Capryol 90: Maisine 35-1 as oil phase and Tween 20 with Lutrol 
E400 as surfactant mixture (Smix). The liquid formulations were adsorbed 
onto Aerosil 200 in a ratio of 1: 0.25 % w/w to convert them into a solid form. 
The formulations were evaluated for globule size, zeta potential, and emulsion 
properties. Transmittance study, scanning electron microscopy, and in-vitro 
dissolution studies were carried out. Biochemical studies were carried out 
using a triton-induced hyperlipidemia model in Wistar rats. The developed 
formulations exhibited some desirable characteristics of self-emulsifying 
systems with nano-sized globules in the range 119.8 to 228.9 nm, rapid 
emulsification in approximately 60 s and transmittance of close to 100 %. In-
vitro dissolution studies on the developed formulations indicate a 4-fold 
increase in drug release in 10 min, compared to the pure drug (ROC) while 
pharmacodynamic data showed significant improvement in oral bioavailability 
compared to the pure drug. the results concluded that the developed 
formulation containing the oils, LAS and combination of capryol 90 with 
Maisine 35-1, has the capability to improve the solubility and bioavailability of 
rosuvastatin calcium when formulated as a self-nanoemulsifying product. 
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Sujit Arun Desai et al., (2015), was formulated and liquid SMEDDS  of  
Lovastatin and evaluated for its transparency, droplet size, zeta potential, 
viscosity, conductivity, percentage assay, and phase separation study. The 
micro emulsion produced by water titration method shows good particle size 
(95 nm). Refractive index and % transmittance showed good isotropic 
formulation. Solubilisation capacity of the system was also determined. An 
accelerated stability study of optimized system was carried out to check the 
stability of the formulation. The prepared micro emulsion was compared with 
the pure drug solution and commercially available Lovastatin tablet for in-vitro 
drug release. It revealed overall increase in release from micro emulsion 
(76.72%) compared to Lovastatin marketed tablet formulation (52.3%). 
Comparative oral absorption of Lovastatin from the micro emulsion and 
suspension of the commercially available Lovastatin was investigated through 
an in-vivo study in a rat model. FTIR studies revealed that there is no physical 
interaction between drug and excipients. 
Anna Czajkowska-Kosnik et al., (2015), designed and characterized 
liquid and solid self-emulsifying drug delivery systems (SEDDS) for poorly 
soluble drug atorvastatin. To optimize the composition of liquid atorvastatin-
SEDDS, solubility tests, pseudoternary phase diagrams, emulsification 
studies and other in vitro examinations (thermodynamic stability, droplet size 
and zeta potential analysis) were performed. Due to the disadvantages of 
liquid SEDDS (few choices for dosage forms, low stability and portability 
during the manufacturing process), attempts were also made to obtain solid 
SEDDS. Solid SEDDS were successfully obtained using the spray drying 
technique. Overall, the studies demonstrated the possibility of formulating 
liquid and solid SEEDS as promising carriers of atorvastatin. SEDDS, with 
their unique solubilization properties, provide the opportunity to deliver the 
lipophilic drugs to the gastrointestinal tract in a solubilized state, thus 
enhancing bioavailability of BCS class 2 drugs. 
Vikas Bhandari et al., (2015), developed self emulsifying drug 
delivery system in liquid and then convert it into a pellet form that would 
result in improved solubility, dissolution and permeability of the poorly water 
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soluble drug carvedilol. Pellets were prepared using extrusion-
spheronization technique incorporating liquid SEDDS (carvedilol, capmul 
MCM EP, cremophore EL, tween 20, propylene glycol), adsorbents ( and 
crospovidone), microcrystalline cellulose and binder (povidone K-30). Ternary 
phase diagram was constructed to identify different oil-surfactant-
cosurfactant mixtures according to the proportion of each point in it. The 
optimal CAR-SEDDS pellets showed a quicker redispersion with a droplet 
size of the reconstituted microemulsion being 160.47 nm, which was almost 
unchanged after solidification. SEM analysis confirmed good spherical 
appearance of solid pellets; DSC and XRD analysis confirmed that there was 
no crystalline carvedilol in the pellets. Pellets were then capable of 
transferring lipophilic compounds into the aqueous phase and significantly 
enhancing its release with respect to pure drug. 
Vidyadhara. S et al., (2015), formulated and evaluated Rosuvastatin 
SMEEDS.  The SMEDDS were prepared by simple admixing method using 
Capmul MCM and Capryol 90 as oils, Polaxomer 407 as surfactant and 
Transcutol HP and Soluphor P as co surfactants. The liquid SMEDDS were 
then converted into free flowing powder by adsorbing onto solid carrier 
magnesium aluminium silicate. Then the formulations were evaluated for 
particle size, phase separation, droplet size, drug content and for in vitro drug 
release. The FTIR and DSC analysis on optimized formulations revealed that 
there were no major interactions between drug and excipients. Among the 
prepared SMEEDS the formulations prepared with oil to co surfactant ratios of 
1:3 shows highest rates of dissolution. 
Krishna mohan chinnala et al., (2015), formulated Self micro emulsion 
of Furosemide which emulsify when exposed to the aqueous phase, and 
evaluated their properties and invitro release studies and determined whether 
they are able to improve oral bioavailability. Formulations from A to D, 
nonionic surfactant Tween 20 was used, and formulations E to H nonionic 
surfactant Cremophore RH 40 was used. From A-H Ethanol & oleic acid were 
used as co-surfactant and oil phase respectively. The minimal emulsification 
time was found with the formulations F(49sec), G (57sec), H (53sec) &D 
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(58sec). The highest emulsification time was found to be in the formulations A 
(1.23min). This may be due to the high viscosity of Tween 20. If the viscosity 
of the oil and co-surfactant used is also high or the content of Tween 20 is 
very high will lead to a low emulsification rate and the emulsification time will 
be greater. 
Parul jaiswal et al., (2014), developed Self Micro Emulsifying drug 
delivery system of Telmisartan to overcome the problems of poor solubility 
and bioavailability. The formulation strategy included selection of oil phase 
based on saturated solubility studies and surfactant and co-surfactant 
screening on the basis of their emulsification ability. Ternary phase diagrams 
were constructed to identify the self-emulsifying region using a dilution 
method. The prepared formulations of SMEDDS were evaluated for their drug 
content, loading efficiency, morphology, globule size determination. Solid-
SMEDDS were prepared by adsorption technique using microcrystalline 
cellulose (1% w/w) and were evaluated for micromeritic properties, scanning 
electron microscopy, differential scanning calorimetry, X-ray diffraction.The 
formulation containing om (20 mg), castor oil (30% w/w), tween 20 (55% w/w), 
propylene glycol (15% w/w) was concluded to be optimized. The optimized 
SMEDDS and solid-SMEDDS exhibited 100% in vitro drug release up to 120 
min, which was significantly higher (P < 0.05, t-test) than that of the pure drug. 
Solid-SMEDDS may be considered as a better solid dosage form as solidified 
formulations are more ideal than liquid ones in terms of its stability. These 
results suggest the potential use of SMEDDS and solid-SMEDDS to improve 
the dissolution and hence oral bioavailability of poorly water-soluble drugs like 
telmisartan through oral route. 
Ahmed A. Hussein et al., (2014), developed solid and liquid self-
microemulsifying drug delivery system of poorly water soluble drug 
mebendazole using Aerosil 200 as solid carrier. Oleic acid, tween 80 and 
polypropylene glycol were selected as oil, surfactant and co-surfactant 
respectively and for preparation of stable SMEDDS, micro emulsion region 
was identified by using pseudo ternary phase diagram containing different 
proportion of surfactant: co- surfactant (1:1, 2:1 and 3:1), oil and water. In brief 
CHAPTER III                                                          REVIEW OF LITERATURE 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI         41 
 
S/ CoS mix means surfactant to co-surfactant and oil were mixed at ratio of 
1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1 manner. To the resultant mixtures, 
water was added drop wise till the first sign of turbidity in order to identify the 
end point and after equilibrium; if the system became clear then the water 
addition was continued. Prepared optimised formula of microemulsion was 
evaluated for SEM, particle size analysis, polydispersity index, phase 
separation, viscosity determination, zeta potential, in- vitro dissolution study 
and in- vivo studies. The optimized microemulsion was converted into solid 
form by Spray Drying technique by using Aerosil 200 as solid carrier. 
Prepared SMEDDS was characterized for same parameters as that of 
microemulsion. Solid SMEDDS of mebendazole prepared using Aerosil 200 
by spray drying technique showed good drug content uniformity. After 
reconstitution it formed microemulsion with micrometric range. In-vitro drug 
release and in-vivo plasma drug concentration of microemulsion and 
SMEDDS was much higher than that of marketed praparation. Hence lipid 
based drug delivery system may efficiently formulate microemulsion and 
which enhances dissolution rate and thus concomitantly bioavailability. In 
conclusion, self micro emulsifying drug delivery system has become promising 
tool to overcome bioavailability problems due to poor solubility. 
Jawad akram et al., (2014), developed A self micro-emulsifying drug 
delivery system (SMEDDS)  to enhance diffusion rate and oral bioavailability 
of Flurbiprofen. The solubility of Flurbiprofen was checked in different oils, 
surfactants, and co-surfactants and ternary phase diagrams were constructed 
to evaluate the micro-emulsion domain. The Flurbiprofen SMEDDS was 
prepared using Capmul MCM (oil), Tween 80 (surfactant), and polyethylene 
glycol 400 (co-surfactant). The particle size distribution, zeta potential, and 
polydispersity index were determined and found to be 12.3 nm, −0.746, and 
0.138, respectively. Diffusion rate of Flurbiprofen was measured by In- Vitro 
dialysis bag method using phosphate buffer pH 6.8 as diffusion media. 
Developed high-performance liquid chromatography method was used to 
determine drug content in diffusion media. Oral bioavailability of Flurbiprofen 
SMEDDS was checked by using mice model. Results of diffusion rate and 
oral bioavailability of Flurbiprofen SMEDDS were compared with those of pure 
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drug solution and of marketed formulation. Diffusion of Flurbiprofen SMEDDS 
showed maximum drug release when compared to pure drug solution and 
marketed formulation. The area under curve and time showed significant 
improvement as the values obtained were 607ng h/mL and 1 h for SMEDDS 
in comparison to 445.36 and 1.36 h for market formulation suggesting 
significant increase (p<0.01) in oral bioavailability of Flurbiprofen SMEDDS. 
Yeole Monali et al., (2014) , developed a solid self-micro emulsifying 
drug delivery system (SMEDDS) of Racecadotril. Design of SMEDDS 
formulations helps to improve the oral absorption of highly lipophilic 
compounds. For formulation of stable SMEDDS, micro emulsion region was 
identified by constructing Pseudo ternary phase diagram for selected oil, 
surfactant, co-surfactant using water titration method. Stable SMEDDS was 
prepared in the ratio of 4:6 using combination of Capryol 90 and Captex 200 
in the ratio of (1:1) as an oil, and Cremophore EL and Transcutol at the km 
value of 2:1. And the prepared liquid SMEDDS were evaluated for all 
parameters. Then the liquid SMEDDS were converted into solid SMEDDS 
using Aerosil 200 by adsorption technique. Prepared S-SMEDDS were 
evaluated for micromeretic properties, drug content, dispersibility test, self 
micro emulsification time, globule size, transparency test, in vitro drug release 
and in vivo study on male wistar albino rats. From the result it showed that 
drug released from S-SMEDDS formulations were found to be significantly 
higher as compared with that of pure drug and marketed formulation and from 
in vivo study it was found that S-SMEDDS showed lower frequency, stool 
volume and wet diarrheal drop as compared to L-SMEDDS, Plain drug and 
marketed formulation. Thus study concluded with S-SMEDDS provides useful 
solid dosage form to improve solubility and dissolution rate of Racecadotril 
and concomitantly bioavailability. 
Maria Saifee et al., (2013), developed solid self micro emulsifying drug 
delivery system (S-SEDDS) with Aerosil 200 for enhancement of dissolution 
rate of model drug Glibenclamide (GBM). SEDDS was prepared using 
Capmul MCM C8TM, Cremophor RH 40TM, and Transcutol PTM as oil, 
surfactant and co-surfactant respectively. For formulation of stable SEDDS, 
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micro emulsion region was identified by constructing pseudo ternary phase 
diagram containing different proportion of surfactant: co-surfactant (1:1, 2:1 
and 3:1), oil and water. Prepared SEDDS was evaluated for turbidity 
measurement, globule size and zeta potential, viscosity determination and % 
transmittance. S-SEDDS was prepared by adsorption technique using Aerosil 
200 as solid carrier. Prepared S-SEDDS was evaluated for flow properties, 
drug content, and FTIR, SEM, DSC and in-vitro dissolution study. Results 
showed that prepared liquid SEDDS passed all evaluation tests. Globule size 
was found to be 142.8 nm with polydispersity index 0.396. S-SEDDS showed 
good flow property and drug content. From the experiment, it is clear that 
even after conversion of the liquid SEDDS into the solid one there was no 
significant alteration in the properties of solid SEDDS. In-vitro dissolution 
studies showed that there was enhancement of dissolution rate of GBM as 
compared with that of plain drug and marketed formulation. From the results it 
is concluded that, Aerosil 200 can be used to develop S-SEDDS by 
adsorption technique to enhance dissolution rate of poorly water soluble 
model drug GBM. 
Pranav V. Patel et al., (2013), developed and evaluated self micro 
emulsifying drug delivery system of Tacrolimus to enhance the poor solubility 
and bioavailability of tacrolimus. Solubility of the tacrolimus was estimated in 
various oils, surfactants, and co-surfactants. Various in vitro tests such as 
percentage transmittance, emulsification time, cloud point, precipitation, and 
thermodynamic stabilities were used to find out optimized formulations. 
Optimized liquid self micro-emulsifying (SMEDDS) were characterized by 
particle size analysis and converted in solid by using the Florite RE as an 
adsorbent, which is further characterized by differential scanning calorimetry 
(DSC), scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier 
transform infrared spectroscopy (FTIR), and particle size analysis. The 
optimized liquid SMEDDS formulation contained 10% Lauroglycol FCC as an 
oil, 60% Cremophor RH, and 30% PEG (polyethylene glycol) 400 as a 
surfactant and co-surfactant respectively. The optimized liquid and solid 
SMEDDS showed higher drug release than the marketed capsule and pure 
API (active pharmaceutical ingredient) powder. For optimized liquid SMEDDS 
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and solid SMEDDS, the globule sizes were found 113 nm and 209 nm 
respectively. The solid state characterization of solid-SMEDDS by SEM, DSC, 
FTIR, and XRD revealed the absence of crystalline tacrolimus in the solid-
SMEDDS. Shelf-lives for liquid SMEDDS and solid SMEDDS were found to 
be 1.84 and 2.25 year respectively The results indicate that liquid SMEDDS 
and solid SMEDDS of tacrolimus, owing to nano-sized, have potential to 
enhance the absorption of the drug.. 
Hyma. P et al., (2013), developed self-microemulsifying drug delivery 
system (SMEDDS) of a poorly water soluble drug, pioglitazone.  Phase 
solubility studies were conducted for the maximum solubility of pioglitazone. 
Highest was found in Tween 80 (surfactant) polyethylene glycol 400 
(cosurfactant) and cottonseed oil. Ternary phase diagrams were constructed 
to evaluate microemulsion regions. FTIR analysis was done for investigating 
the drug–excipient interactions. The mean globule size of SMEDDS was 
observed to be below 200 nm for the optimized formulations and the zeta 
potential was negative. The dissolution of emulsion formulations was 
compared with commercial tablets; the results indicated that the rate of 
dissolution of developed formulations containing pioglitazone was 2 to 3 folds 
increased compared with that of commercial tablets. SEM studies were done 
for the shape and morphology of the globules. Thus, SMEDDS can be 
regarded as novel and commercially feasible alternative to the current 
pioglitazone formulations. 
Smita S. Pimple et al., (2013), were developed Risperidone Self-micro 
emulsifying drug delivery system to enhance the solubility and dissolution of 
Risperidone, and evaluated for their potential. Primary tools used to select the 
components and to optimize the components of liquid SMEDDS were 
solubility study, emulsification ability ternary phase diagrams and central 
composite design (CCD). The liquid SMEDDS were formulated using Capryol 
m990 as oil, Cremophore EL and Transcutol Pas surfactant and co-surfactant. 
The liquid SMEDDS were evaluated for globule size, transmittance and self-
emulsification time. Then the liquid SMEDDS converted into solid SMEDDS 
using Aerosil 200 by spray drying method. The SEM analysis, DSC, XRD 
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spectra reveal the presence of Risperidone in molecular state in solid 
SMEDDS. The in vitro dissolution study indicated improved dissolution 
characteristics with higher percent drug release for solid SMEDDS (92.30%) 
compared to marketed formulation(80.48%). 
Bharat bhushan subudhi et al., (2013), developed  self-micro 
emulsifying drug delivery system (SMEDDS) of Ibuprofen for investigating its 
intestinal transport behavior using the single-pass intestinal perfusion (SPIP) 
method in rat. Ibuprofen loaded SMEDDS (ISMEDDS) was developed and 
was characterized. The permeability behavior of Ibuprofen over three different 
concentrations (20, 30, and 40 µg/mL) was studied in each isolated region of 
rat intestine by SPIP method at a flow rate of 0.2 mL/min. The human 
intestinal permeability was predicted using the Lawrence compartment 
absorption and transit (CAT) model since effective permeability coefficients 
values for rat are highly correlated with those of human, and comparative 
intestinal permeability of Ibuprofen was carried out with plain drug suspension 
(PDS) and marketed formulation (MF).  The developed ISMEDDS was stable, 
emulsified upon mild agitation with 44.4 nm ± 2.13 and 98.86% ± 1.21 as 
globule size and drug content, respectively. Higher  in colon with no 
significant  difference in jejunum, duodenum, and ileum was observed. The 
estimated human absorption of Ibuprofen for the SMEDDS was higher than 
that for PDS and MF. Developed ISMEDDS would possibly be advantageous 
in terms of minimized side effect, increased bioavailability, and hence the 
patient compliance. 
Shailesh R. Prajapati et al., (2012), developed a self-microemulsifying 
drug delivery system (SMEDDS) of Olmesartan medoxomil ( OLM) to 
enhance the oral absorption of OLM. The solubility of OLM in various oils, 
surfactants, and co-surfactants was determined. Pseudoternary phase 
diagrams were constructed using Acrysol EL 135, Tween 80, Transcutol P, 
and distilled water to identify the efficient self-microemulsification region. 
Prepared SMEDDS was further evaluated for its emulsification time, drug 
content, optical clarity, droplet size, zeta potential, in vitro dissolution, and in 
vitro and ex vivo drug diffusion study. The optimized formulation  contained 
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OLM (20 mg), Tween 80 (33%v/v), Transcutol P (33%v/v), and Acrysol EL 135 
(34%v/v) had shown the smallest particle size, maximum solubility, less 
emulsification time, good optical clarity, and in vitro release. The in vitroand ex 
vivo diffusion rate of the drug from the SMEDDS was significantly higher than 
that of the plain drug suspension. It was concluded that SMEDDS would be a 
promising drug delivery system for poorly water-soluble drugs by the oral 
route. 
Arundhati Bhattacharyya et al., (2012), developed  a self-emulsifying 
drug delivery system sss(SEDDS) of amphotericin B and  evaluated the 
dissolution and permeability of amphotericin B from the formulation. The 
solubility of amphotericin B in various oils, surfactants and co-surfactants was 
determined. Various SMEDDS formulations were prepared with varying 
amounts of oil, surfactant and co-surfactant. Evaluation parameters for 
formulation optimization were drug content, self-emulsification, droplet size 
analysis, and  precipitation studies. In vitro dissolution was studied in 
comparison to the pure drug. Permeability was studied using non-everted 
intestinal sac method. The optimized formulation consisted of glycerol mono-
oleate (10%, w/w), tween 80 (36%, w/w), polyethylene glycol 400 (27%, w/w), 
and propylene glycol (27%, w/w) with a drug content of about 8 mg per ml. The 
self-emulsifying formulation showed 100% dissolution within 30 minutes 
whereas the pure drug exhibited a very poor rate of dissolution. In vitro 
intestinal permeability was studied by non-everted intestinal sac method using 
rat intestine. The self-emulsifying formulation showed 100% drug permeation 
within 30 minutes compared to negligible permeation from the drug suspension. 
The study was demonstrated that SMEDDS approach may be useful for 
enhancement of dissolution and intestinal permeation of amphotericin B 
belonging to class IV of Biopharmaceutic Classification System. 
Shailesh T. Prajapati et al., (2012), were formulated and evaluated 
Self micro emulsifying drug delivery system (SMEDDS) of  Olmesartan 
medoxomil (OLM) that has absolute bioavailability of only 26% due to the poor 
aqueous solubility (7.75 ߤߤg/ml), to enhance the oral absorption of OLM. The 
solubility of OLM in various oils, surfactants, and cosurfactants was 
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determined. Pseudo ternary phase diagrams were constructed using Acrysol 
EL 135, Tween 80, Transcutol P, and distilled water to identify the effcient 
self-microemulsifcation region. Prepared SMEDDS was further evaluated for 
its emulsifcation time, drug content, optical clarity, droplet size, zeta potential, 
in vitro dissolution, and in vitro and ex vivo drug diffusion study. The optimized 
formulation S2 contained OLM (20 mg), Tween 80 (33%v/v), Transcutol P 
(33%v/v), and Acrysol EL 135 (34%v/v) had shown the smallest particle size, 
maximum solubility, less emulsifcation time, good optical clarity, and in vitro 
release. The in vitro and ex vivo diffusion rate of the drug from the SMEDDS 
was signifcantly higher than that of the plain drug suspension. It was 
concluded that SMEDDS would be a promising drug delivery system for 
poorly water-soluble drugs by the oral route. 
Urvashi goyal et al., (2012), formulated Self-micro emulsifying drug 
delivery system (SMEDDS) of lovastatin to overcome the problems of poor 
solubility and bioavailability. The formulation strategy included selection of oil 
phase based on saturated solubility studies and surfactant and co-surfactant 
screening on the basis of their emulsification ability. Ternary phase diagrams 
were constructed to identify the self-emulsifying region. Capryol 90 (20 %) as 
oil, Cremophore RH40 (40 %) as surfactant and Transcutol P (40 %) as co-
surfactant were concluded to be optimized components. The prepared 
SMEDDS was characterized through its droplet size, zeta potential, 
emulsification time, rheological determination and transmission electron 
microscopy. The optimized formulation exhibited 94 % in vitro drug release, 
which was significantly higher than that of the drug solution. In vivo studies 
using the Triton-induced hyperlipidemia model in Wistar rats revealed 
considerable reduction in lipid levels compared to pure lovastatin. The study 
confirmed the potential of lovastatin SMEDDS for oral administrations. 
Suryakanta Swain et al., (2012), developed and evaluated novel solid 
self-nano emulsifying drug delivery systems (S-SNEDDS) of valsartan with 
improved oral bioavailability, and evaluated their in vitro and in vivo 
performance. Preliminary solubility studies were carried out and 
pseudoternary phase diagrams were constructed using blends of oils (Capmul 
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MCM), surfactant (Labrasol), and co-surfactant (Tween 20). The SNEDDS 
were systemically optimized by response surface methodology employing 
methodology employing 32 Box- Behnken design. The prepard SNEDDS were 
characterized for viscosity refractive index, globule size, zeta potential, and 
TEM. Optimized liquid SNEEDS were formulated into free flowing granules by 
adsorption on the porous carriers like Aerosil 200, Sylysia (350) and Neusilin 
US2, and compressed into tablets. In vitro dissolution studies of S-SNEDDS 
revealed that 3 to 3.5 fold increased in dissolution rate of the drug due to 
enhanced solubility. In vivo pharmacodynamic studies in wistar rats showed 
significant reduction in mean systolic BP by S-SNEDDS via oral suspension 
(p<0;05)owing to the drug absorption through lymphatic pathways. Solid-state 
characterization of S-SNEDDS using FT- IR and powder XRD studies 
confirmed lack of any significant interaction of drug with lipidic excipients and 
porous carriers. Further, the accelerated stability studies for 6 month revealed 
that S-SNEDDS are found to be stable without any change in physiochemical 
properties. Thus the present studies demonstrated the bio availability 
enhancement potential of porous carriers based S-SNEDDS for a BCS class 
II drug, valsartan. 
Rohit ramesh shah et al., (2012), developed self-micro emulsifying 
drug delivery system (SMEDDS) to enhance the oral absorption of the poorly 
water-soluble drug, Efavirenz. The influence of the oil, surfactant and co-
surfactant types on the drug solubility and their ratios on forming efficient and 
stable SMEDDS were investigated in detail. The SMEDDS were characterized 
by morphological observation, droplet size and zeta potential determination, 
freeze thawing and in vitro release study. The optimum formulation consisted 
of 45% Acconon MC-8 EP, 26.66% Cremophor EL and 13.33% Polyethylene 
glycol 400. In vitro release test showed a complete release of Efavirenz from 
SMEDDS in an approximately 4 h. The absorption of Efavirenz from SMEDDS 
showed increase in absorption compared with that of the marketed 
formulation. This study demonstrated the promising use of SMEDDS for the 
delivery of Efavirenz by the oral route.  
Dhivyakumar bora et al., (2012),  formulated self microemulsifying 
drug delivery system (SMEDDS) of Atorvastatin (BCS class II ),which is very 
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slightly soluble in water. The solubility of atorvastatin in individual 
microemulsion components viz. oil and surfactants was determined. The 
surfactants were screened for emulsification ability. Based on the solubility 
determinations and emulsification properties sunflower oil and surfactants 
cremophor RH 40 and capmul MCM C8 were selected for further study. The 
solubility of atorvastatin in different ratios of selected oil and surfactants was 
determined. The composition of oil:surfactants with maximum solubility for 
atorvastatin was used for SMEDDS formulation. Pseudoternary phase 
diagrams were used to evaluate the microemulsification existence area. 
Formulation development and screening was done based on results obtained 
from phase diagrams and characteristics of resultant microemulsions. The 
microemulsions were evaluated for emulsion droplet size, self emulsification 
and phase separation, In vitro dissolution and stability. The SMEDDS 
formulation showed complete release in 30 min. as compared with the plain 
drug, which showed a limited dissolution rate. Thus the study demonstrated 
that SMEDDS is a promising drug delivery system to enhance the 
bioavailability of poorly water soluble drugs.  
        Solanki S et al., (2012), enhanced the dissolution rate and bioavailability 
of Ampelopsin, one of the most common flavonoids by developing 
microemulsion. Capmul MCM-based ME formulation with Cremophor EL as 
surfactant and Transcutol as cosurfactant was developed for oral delivery of 
ampelopsin. The optimised microemulsion formulation containing ampelopsin, 
Capmul MCM (5.5%), Cremophor EL (25%), Transcutol P (8.5%), and distilled 
water showed higher in vitro drug release, as compared to plain drug 
suspension and the suspension of commercially available tablet. These 
results demonstrate the potential use of ME for improving the bioavailability of 
poor water soluble compounds, such as ampelopsin[1]. 
Gundogdu E et al., (2012), formulated imatinib (IM) loaded to oral 
water-in-oil (w/o) microemulsions as an alternative formulation for cancer 
therapy and evaluated the cytotoxic effect of microemulsions Caco-2 and 
MCF-7. Moreover, permeability studies were also performed with Caco-2 
cells. According to cytotoxicity studies, all formulations did not exert a 
cytotoxic effect on Caco-2 cells. The permeability studies of IM across Caco-2 
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cells showed that permeability value from apical to basolateral was higher 
than permeability value of other formulations. In conclusion, the 
microemulsion formulations as a drug carrier, especially M3IM formulation, 
may be used as an effective alternative breast cancer therapy for oral delivery 
of Imatinib. 
Ramesh jakki et al., (2012), prepared a self-micro emulsifying drug 
delivery system (SMEDDS) for enhan- cement of oral bioavailability of 
domperidone, a poorly water soluble drug. The solubility of the drug was 
determined in various vehicles. A pseudo ternary phase diagram was 
constructed to identify the self-micro emulsification region. The in vitro self-
micro emulsification properties and droplet size analysis of SMEDDS were 
studied following their addition to water under mild agitation. Further, the 
resultant formulations were investigated for clarity, phase separation, globule 
size, effect of pH and dilutions (1:100, 1:500, 1:1000) and freeze-thaw stability. 
The optimized formulation of SMEDDS used for in vitro dissolution and 
bioavailability assessment, contained oil (Labrafac CC, 25 %, m/m), 
surfactant (Tween 80, 55 %, m/m), and co-surfactant (Transcutol, 20 %, 
m/m). The preliminary oral bio- availability of domperidone from SMEDDS 
was 1.92-fold higher compared to that of domperidone suspension in rats. The 
results suggested a significant increase (p < 0.05) in oral bioavailability of 
domperidone from SMEDDSS than that of the conventional formulation. 
Du H et al., (2012), reform the dosage forms of andrographolide to 
improve its aqueous solubility and oral bioavailability. A formulation of O/W 
microemulsion consisting of an oil phase of isopropyl myristate, a surfactant 
phase of Tween 80, a co-surfactant of alcohol, and water was found to be 
ideal, with mean droplet size of 15.9 nm, a high capacity of solubilisation for 
andrographolide. Such an andrographolide-loaded microemulsion was stable 
by monitoring the time, temperature and gravity-dependent change, and had a 
much better anti-inflammatory effect and a higher biological availability than 
andrographolide tablets. 
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Park JH et al., (2011), investigated the effects of silymarin, on oral 
bioavailability of paclitaxel in rats, and to compare pharmacokinetic parameters 
of paclitaxel between a commercial formulation of paclitaxel and a paclitaxel 
microemulsion. Oral bioavailability of paclitaxel in a Taxol® formulation was 
enhanced in the combination with silymarin. In particular, the mean maximum 
plasma concentration and the mean area under the plasma concentration-time 
curve of paclitaxel in the formulation were significantly increased 3- fold and 5-
fold compared with control, respectively, following oral co-administration with 
10mg/kg of silymarin (p<0.01). When the paclitaxel microemulsion was co- 
administered with silymarin orally, it caused a maximum increase in the 
absolute bioavailability of paclitaxel. 
Hetal thaker et al., (2011), formulated and evaluated Raloxifene self 
micro emulsifying drug delivery system. Raloxifene is a second generation 
selective estrogen receptor modulator used to prevent osteoporosis in 
postmenopausal women. The bioavailability of drug is only 2% because of 
extensive hepatic first pass metabolism. The SMEDDS were prepared by 
employing dimple admixing method using Capmul MCM C8, Tween 20 and 
akrysol K140 and PEG 200. The concentration range of surfactant and co-
surfactant was choose by constructing Pseudo ternary phase diagram. The 
prepared formulations were characterized for drug loading, size, 
transparency, zeta potential and in vitro intestinal permeability. The results 
indicated that high drug loading, optimum size and desired zeta potential was 
achieved. The TEM studies indicated the absence of aggregation. The in vitro 
permeability results showed that the permeation of the drug from the self 
micro emulsion was significantly higher than that obtained from the drug 
dispersion and marketed formulation. 
Sajal Kumar Jha et al., (2011), developed an oral microemulsion 
formulation for enhancing the bioavailability of famotidine is a BCS class III 
drugs which are known to have high solubility but low permeability. An Olive 
oil based microemulsion formulation with Tween 80 as surfactant and PEG 
400 as cosurfactant was developed for oral delivery of famotidine. A single 
isotropic region, which was considered to be a bicontinuous microemulsion, 
was found in the pseudoternary phase diagrams developed at various 
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Tween80: PEG 400: oil ratios. The microemulsion system was also 
investigated in terms of other characteristics, such as viscosity, pH, 
conductivity, clarity, particle size, in vitro drug release, in vitro intestinal 
permeability study compared to the plain drug solution (64.18%). The 
developed microemulsion system improved the permeability (93.43%) by 
increasing the lipophillicity due to the oil phase and also by destabilizing the 
membrane stability due the surfactants and may be used as an enhanced 
delivery of BCS class III drugs. 
M. Nagaraju Patro et al., (2010), developed a stable self micro 
emulsifying drug delivery system (SMEDDS) of valproic acid (VPA) and 
evaluated its in vitro potential. The solubility of VPA was determined in various 
vehicles. Pseudo ternary phase diagrams were used to evaluate the micro 
emulsification existence area and the release rate of VPA was investigated 
using a dissolution method. SMEDDS were characterized for clarity, 
precipitation and particle size distribution. Formulation development and 
screening was done based on results of solubility from phase diagram. The 
optimized formulation used for in vitro dissolution was composed of castor oil 
(38.4 %), Cremaphor RH 40 (42.4 %), PEG 400 (14.4 %). The SMEDDS 
formulation showed complete release in 15 min. as compared with the plain 
drug and conventional marketed formulation which showed a limited 
dissolution rate. VPA loaded SMEDDS were subjected to various conditions 
of storage as per ICH guidelines for 3 months. VPA SMEDDS successfully 
withstood the stability testing. It has been found that dissolution profile of 
valproic acid from SMEDDS was much improved than valproic acid. 
Maulik J.Patel et al., (2010), developed Self-micro emulsifying drug 
delivery system (SMEDDS) of Lovastatin to increase the solubility and oral 
bioavailability of Lovastatin. To formulate the SMEDDS, solubility study was 
performed in different excipients and the excipients are selected based on the 
solubility of lovastatin. Microemulsion region was decided by preparing ternary 
phase diagram. Drug excipients interaction was demonstrated by performing 
DSC and FTIR studies. After preliminary study, SMEDDS were formulated 
using sunflower oil, Acrsol K 140,  Capmul MCM C8, and PEG 400 as oil, 
surfactant, co-surfactant and co-solvent respectively. The SMEDDS were 
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prepared by simple admixing method. The prepared SMEDDS were evaluated 
for macroscopic evaluation visal assessments, self emulsification, 
transmittance test, droplet size, zeta potential and stability study, in vitro 
dissolution. The droplet size was found to be 18 t0 24 nm. Drug release was 
found to be up to 92% in one hour. Release data was compare with marketed 
product. It showed that the release from the SMEDDS was better than that of 
the marketed formulation. It was concluded that the SMEDDS is a promising 
drug delivery for enhancing oral bioavailability of poorly soluble drugs. 
Jill B. Shukla et al., (2010), formulated Self micro emulsifying drug 
delivery system (SMEDDS) of Candesartan cilexetil and evaluated it’s in vitro 
and in vivo potential. The solubility of Candesartun cilexetil was determined in 
various vehicles. Pseudo ternary phase diagrams were used to evaluate the 
micro emulsification existence area, and the release rate of Candesartann 
cilexetil was investigated by using  in vitro dissolution studies. Formulation 
development and screening was done by the results obtained from the phase 
diagrams. The optimized formulation was composed of Transcutol P as an oil, 
Capryol 90 as surfactant and plurol oleique as co-surfactant. And this was 
evaluated for various parameters the SMEDDS formulation showed complete 
release in 60 minutes. Thus the study confirmed that the SMEDDS 
formulation can be used as a possible alternative to traditional oral 
formulations of Candesartan cilexetil to improve its bioavailability. 
Cui J et al., (2009), prepared a self-microemulsifying drug delivery 
system to improve the solubility and oral absorption of curcumin. Suitable 
compositions of SMEDDS formulation were screened via solubility studies of 
curcumin and compatibility tests. The optimal formulation of SMEDDS was 
comprised of 57.5% surfactant, 30.0% co- surfactant and 12.5% oil (ethyl 
oleate). The solubility of curcumin (21 mg/g) significantly increased in 
SMEDDS. The average particle size of SMEDDS-containing curcumin was 
about 21 nm when diluted in water. No significant variations in particle size 
and curcumin content in SMEDDS were observed over a period of 3 months 
at 4 degrees C. The results of oral absorption experiment in mice showed that 
SMEDDS could significantly increase the oral absorption of curcumin 
compared with its suspension. 
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Mandawgadea SD et al., (2008) has investigated SMEDDS of β-
Artemether (BAM) using a novel, indigenous natural lipophile (N-LCT) as an 
oily phase. SMEDDS based on N-LCT and commercially available modified oil 
(capryol90) was formulated. Comparative in vivo anti-malarial performance of 
the developed SMEDDS was evaluated against the (Larither) in Swiss male 
mice infected with lethal ANKA strain of Plasmodium berghei. Both the BAM–
SMEDDS showed excellent self- microemulsification efficiency and released 
>98% of the drug in just 15 min whereas Larither showed only 46% drug 
release at the end of 1h. The anti-malarial studies revealed that BAM–
SMEDDS resulted in significant improvement in the anti-malarial activity (P 
<0.05) as compared to that of (Larither) and BAM solubilized in the oily 
phases and surfactant. 
Ying chen et al (2008), formulated and evaluated self-microemulsifying 
drug delivery system (SMEDDS of vinpocetine (VIP), a poor water-soluble 
drug )  to increase the solubility, dissolution rate and oral bioavailability. The 
formulations of VIP-SMEDDS were optimized by solubility assay, compatibility 
tests, and pseudo-ternary phase diagrams analysis. The optimal ratio in the 
formulation of SMEDDS was found to be Labrafac : oleic acid : Cremophor EL 
: Transcutol P=40 : 10 : 40 : 10 (w/w). The average particle diameter of VIP 
was less than 50 nm. In vitro dissolution study indicated that the dialysis 
method in reverse was better than the ultra filtration method and the dialysis 
method in simulating the drug in vivo environment. Comparing with VIP crude 
drug power and commercial tablets, (− ) VIP-SMEDDS caused a 3.4- and 2.9-
fold increase in the percent of accumulated dissolution at 3 h. Further study 
on the absorption property of VIP-SMEDDS employing in situ intestine of rats 
demonstrated that VIP in SMEDDS could be well-absorbed in general 
intestinal tract without specific absorption sites. In addition, the developed 
SMEDDS formulations significantly improved the oral bioavailability of VIP in 
rats. Relative bioavailability of (−) VIP-SMEDDS and (+ ) VIP-SMEDDS 
increased by 1.85- and 1.91-fold, respectively, in relative of VIP crude powder 
suspension. The mechanisms of enhanced bioavailability of VIP might 
contribute to the improved release, enhanced lymphatic transport, and 
increased intestinal permeability of the drug. 
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Ashok R. Patel et al., (2007), developed SMEDDS (self- 
microemulsifying drug delivery system) of fenofibrate and evaluated its in vitro 
and in vivo potential. The solubility of fenofibrate was determined in various 
vehicles. Pseudoternary phase diagrams were used to evaluate the 
microemulsification existence area, and the release rate of fenofibrate was 
investi- gated using an in vitro dissolution test. SMEDDS formulations were 
tested for microemulsifying properties, and the resultant microemulsions were 
evaluated for clarity, precipitation, and particle size distribution. Formulation 
development and screening was done based on results obtained from phase 
diagrams and characteristics of resultant microemulsions. The optimized 
formulation was composed of Labrafac CM10 (31.5%), Tween 80 (47.3%), and 
polyethylene glycol 400 (12.7%). The SMEDDS formulation showed complete 
release in 15 min-utes as compared with the plain drug, which showed a limited 
dissolution rate. Comparative pharmacodynamic evaluation was investigated in 
terms of lipid-lowering efficacy, using a Triton-induced hypercholesterolemia 
model in rats. The SMEDDS formulation significantly reduced serum lipid levels 
in phases I and II of the Triton test, as compared with plain fenofibrate. The 
optimized formulation was then subjected to stability studies and was found to be 
stable over 12 months. Thus, the study confirmed that the SMEDDS formulation 
can be used as a possible alternative to traditional oral formulations of 
fenofibrate to improve its bioavailability 
Ghosh PK et al., (2006), developed microemulsion system of Acyclovir 
for improvement of oral bioavailability. A labrafac-based microemulsion 
formulation with labrasol as surfactant and plurol oleique as co-surfactant was 
developed for oral delivery of Acyclovir. With the increase of labrasol 
concentration, the microemulsion region area and the amount of water and 
labrafac solubilized into the microemulsion system increased; however, the 
increase of plurol oleique percentage produced opposite effects. Acyclovir, a 
poorly soluble drug, displayed high solubility in a microemulsion formulation 
using labrafac (10%), labrasol (32%), plurol oleique (8%), and water (50%). 
The in vitro intraduodenal diffusion and in vivo study revealed an increase of 
bioavailability (12.78 times) after oral administration of the microemulsion 
formulation as compared with the commercially available tablets. 
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CHAPTER - IV 
AIM OF THE WORK 
 
Most of the New Chemical Entities (NCE) that are being discovered 
are lipophillic in nature and have poor aqueous solubility, thereby posing 
problems in their formulation into delivery systems. Because of their low 
aqueous solubility and low permeability, dissolution and/or release rate from 
the delivery system forms the rate-limiting step in their absorption and 
systemic availability. More than 60% of potential drug products suffer from 
poor water solubility. For the therapeutic delivery of such drugs, having poor 
aqueous solubility, number of technologies had been developed like solid 
dispersions, cyclodextrins, micronization, nano particles, permeation 
enhancer, etc. 
Although some approaches are available for enhancing the dissolution 
of poorly soluble drugs, but has certain drawbacks like low drug loading and 
large dose. 
Pitavastatin as a synthetic lipid lowering agent is an inhibitor of 3-
hydroxy-3-methyl-glutaryl-co-enzyme A (HMGCoA) reductase which catalyzes 
the conversion of HMGCoA to mevalonate an early rate -limiting step in 
choloesterol biosynthesis;this then results in a compensatory incresase in the 
expression of LDL receptors on hepatocyte membranies and a stimulation of 
LDL catabolisam. In addition to the ability of HMGCoA reductase inhibitors to 
decrease levels of high sensitivity C reactive protein  (hsCRP),they  also  
possess  pleiotropic   properties  including  endothelilal   function, reducd 
inflammation at the site  of the coronary plaque, inhibiton of platelet 
aggregation  ,and anticoagulant  effects. The absolute oral bioavailability of 
Pitavastatin following oral administration is 58%-60%. It is soluble in ethyl 
alcohol and very slightly soluble in water. (Harish Chander et al., 2011) 
The Self-microemulsifying drug delivery system is one of the 
promising approaches to overcome the formulation difficulties of various 
hydrophobic/lipophillic drugs and to improve the oral bioavailability of poorly 
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absorbed drugs  and also drugs are protected from hostile environment in 
gut. SMEDDS are isotropic mixture of oil, surfactant, drug and sometime 
containing co-surfactant and administered orally which on mild agitation with 
GI fluids forms O/W microemulsion. 
 
The present study is carried out to develop L-SMEDDS and              
S-SMEDDS of Pitavastatin in order to enhance the solubility and bioavailability 
by providing a lipidic environment to the drug which ensure its better solubility.  
The components to prepare the L-SMEDDS are choosed based on the 
solubility studies and % transmittance value. The concentration of components 
is optimized by constructing Pseudo ternary phase diagrams. The liquid 
SMEDDS of pitavastatin are prepared by simple admixing method, and then 
converted into S-SMEDDS on an inert carrier by adsorption technique. The 
best formulation is selected based on the drug content, invitro dissolution 
studies, particle size and solubility studies. The in vitro dissolution profile of S-
SMEDDS of Pitavastatn is compared with the pure drug and conventional 
tablet. 
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CHAPTER-V 
PLAN OF WORK 
1. STANDARD CURVES FOR PITAVASTATIN 
• Preparation of calibration medium 
• Estimation of absorption maximum (λmax). 
• Preparation of standard curve. 
 
2. PREFORMULATION (COMPATABILITY) STUDIES 
• Fourier Transform infra-red spectroscopic study. 
• Differential scanning calorimetric studies. (DSC) 
 
3. FORMULATION OF PITAVASTATIN LIQUID SMEDDS 
                The liquid SMEDDS are prepared by simple admixing method. The 
preparation process involves following steps. 
• Determining solubility of Pitavastatin in various oil, surfactant, 
and co-surfactant. 
• Screening of surfactant and co-surfactant. 
• Construction of Pseudo ternary phase diagram. 
• Formulation of liquid SMEDDS. 
 
4. CHARACTERIZATION OF PITAVASTATIN LIQUID  SMEDDS 
• Visual assessment 
• Dispersibilty test 
• Determination of Self emulsification time. 
• Thermodynamic stability studies. 
• Cloud point measurement. 
• Robustness to Dilution. 
• Refractive index and Percentage Transmittance. 
• Determination of viscosity. 
• Determination of Drug content. 
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5. Conversion of liquid SMEDDS into Solid SMEDDS: 
The liquid SMEDDS are converted into solid SMEDDS by adsorption 
technique. In this method the Liquid SMEDDS are mixed with MCC at 1:1 w/w 
ratio to produce S-SMEDDS.  
6. Characterization of S-SMEDDS: 
• Determination of micromerertic properties 
• Determination of Drug content. 
• Determination of In vitro drug release study. 
• Comparison of release profile with pure drug and conventional 
tablet. 
 
7. Selection on Best formulation: 
The best formulation is selected depending on the results obtained from 
physiochemical characterization, drug content and in vitro drug release 
studies. 
8. Evaluation of Best formulation: 
The best formulation will be evaluated for, 
• Fourier transform infra-red spectroscopic (FT-IR). 
• Scanning Electron Microscopy (SEM). 
• X-ray Powder Diffraction (XRPD). 
• Differential Scanning Colorimetry. 
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CHAPTER -VI 
MATERIALS AND EQUIPMENTS 
MATERIALS USED 
TABLE 1: 
MATERIALS NAME SUPPLIERS 
Pitavastatin Calcium Gift sample from Shasun pharmaceuticals, Cudalore. 
Capryol 90 High Purity Laboratory Chemicals (P) Ltd, Mumbai. 
Oleic acid High Purity Laboratory Chemicals (P) Ltd, Mumbai. 
Sunflower oil Universal Scientific Appliances, Madurai. 
Sesame oil Universal Scientific Appliances, Madurai. 
Castor oil Universal Scientific Appliances, Madurai. 
Tween 20 R.K. Diagnostics, Madurai. 
Tween 80 R.K. Diagnostics, Madurai. 
Cremophor RH 40 Madras pharma, Chennai. 
Span 80 Universal Scientific Appliances, Madurai. 
Micro crystalline cellulose Madras pharma, Chennai. 
Polyethylene glycol 400 Gift sample from Pharmafabrikon, Madurai 
Propylene glycol Gift sample from Pharmafabrikon, Madurai 
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EQUIPMENTS  
 TABLE-2 
 
EQUIPMENTS NAME MANUFACTURER’S 
Electronic weighing balance A & D Company, Japan. 
UV-Visible spectrophotometer Shimadzu Corporation, Japan. 
Infrared spectroscopy Spectrum RX-1, Perkin Elmer, German. 
Differential Scanning 
Calorimeter DSC Q 200, USA. 
Scanning electron microscope Hitachi X650, Tokyo, Japan. 
Particle size analyzer Nano ZS 90, Malvern Instruments Ltd.,UK 
Freeze dryer Lyodel-Delvac Pumps Pvt. Ltd, USA. 
Mechanical shaker Secor, India. 
Dissolution apparatus Labindia – Disso 2000, India. 
Ultra Sonicator Vibronic’s Ultrasonic processor, India. 
X-ray diffractometer Digaku XRD-462, Japan. 
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CHAPTER VII 
DRUG PROFILE 
 
DRUG NAME : PITAVASTATIN 
 
SYNONYM : PITAVASTATIA, PITAVASTATINE, 
 
STRUCTURAL FORMULA : 
 
 
CHEMICAL FORMULA : C25 H24 F NO4 
 
IUPAC NAME :  (3R,5S,6E)-7-[2-2-[(2S)- 
      cyclopropyl-4-(4  
fluorophenyl)quinoline-3-yl]-3,-5-di 
hydroxyhept-6-enoic acid.- 
DESCRIPTION 
 
Nature : An off white to yellowish powder 
 
  Pitavastatin is freely soluble in  
  ethanol and very slightly soluble  
  in water 
Molecular weight : 421.461 g/mol 
pKa : 5.36 
Melting point : >138 oC 
Bolilng point : 692.0±55.0ºC at760mmHg 
Index of Refraction : 1.680 
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HISTORY OF PITAVASTATIN 
                   Pitavastatin (previously known itavastatin, itabavastatin, 
nisvastatin) was discovered in JAPAN by NISSAN CHEMICAL INDUSTRIES 
and developed further by KOWA pharmaceuticals, TOKYO. Pitavastatin was 
approved for use in the united states by the FDA on 08/03/2009 under the 
trade name Livalo. Pitavastatin has been also approved by the Medicines and 
Helathcare products Regulatory Agency (MHRA) in UK on August 2010. 
(Reid,J; Reckless, J.P.D et al 2006)  
PHARMACOLOGY 
       It is a calcium slat of Pitavastatin, a novel statin that induces plaque 
regression and elevates HDL cholesterol level. 
MECHANISM OF ACTION 
 
Pitavastatin competitively inhibits HMG-CoA reductase, which is a 
rate-determining enzyme involved with biosynthesis of cholesterol, in a 
manner of competition with the substrate so that it inhibits cholesterol 
synthesis in the liver. As a result, the expression of LDL-receptors followed 
by the uptake of LDL from blood to liver is accelerated and then the plasma 
TC decreases. Further, the sustained inhibition of cholesterol synthesis in 
the liver decreases level of very low density lipoproteins. 
PHARMACOKINETICS 
 
a) Absorption 
 
       Pitavastatin is rapidly absorbed from the upper gastrointestinal tract 
and peak  concentrations are achieved in one hour after oral administration. 
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Cmax is decreased by 43%, if the drug is taken with a fatty meal. Unchanged 
drug undergoes enterohepatic circulation and is well absorbed from the 
jejunum and ileum. The absolute bioavailability of Pitavastatin is 51%. 
b) Distribution 
Pitavastatin is more than 99% protein bound in human plasma, 
mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of 
distribution is approximately 148 L. Pitavastatin is actively transported into 
hepatocytes, the site of action and metabolism, by multiple hepatic 
transporters including OATP1B1 and OATP1B3. Plasma AUC is variable 
with an approximately 4-fold range between the highest and lowest values. 
Studies with SLCO1B1 (the gene which encodes OATP1B1) suggests that 
polymorphism of this gene could account for much of the variability in AUC. 
Pitavastatin is not a substrate for p-glycoprotein. 
C) Volume of distribution 
Mean volume of distribution at steady-state of Pitavastatin is 
approximately 148 liters. 
 
d) Protein binding: 
>99%,primariliy to albumin and alpha 1-acid glycoprotein. 
 
e) Metabolism 
Mainly by liver through glucuronidation. The principal metabolite is 
the inactive lactone which is formed via an ester-type Pitavastatin 
glucuronide conjugate by UDP glucuronosyltransferase (UGT1A3 and 
2B7). In vitro studies, using 13 human cytochrome P450 (CYP) isoforms, 
indicate that the metabolism of Pitavastatin by CYP is minimal; CYP2C9 
(and to a lesser extent CYP2C8) is responsible for the metabolism of 
Pitavastatin to minor metabolite. 
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f) Excretion 
Unchanged Pitavastatin is rapidly cleared from the liver in the bile, 
but undergoes enterohepatic recirculation, contributing to its duration of 
action. The plasma elimination half-life ranges from 5.7 hours (single dose) 
to 8.9 hours (steady state) and clearance is 23.6 liter/hour. 
g) Route of elimination  
         79% feces 
         15% urine 
DOSAGE FORMS : film coated tablet of varying concentration are available. 
   
          Tablet  oral 1 mg 
          Tablet oral 1.045 mg 
          Tablet oral 2 mg 
          Tablet oral 2.09 mg 
          Tablet oral 4 mg 
          Tablet oral 4.18 mg 
ADVERSE REACTIONS 
Rhabdomyolysis with myoglobinuria and acute renal failure and 
myopathy(including myosistis). 
CONTRAINDICATIONS 
Hypersenstivity to Pitavastatin or any component of the formulation; 
active liver disease;pregnancy, lactation,co-admistered with cyclosporine. 
DRUG INTERACTIONS 
a) Atorvastatin 
The serum concentration of Pitavastatin can be increased when it is 
combined with atorvastatin 
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b) Benzocaine 
The serum concentration of Pitavastatin can be increased when it is 
combined with benzocaine. 
c) Caffeine 
The serum concentration of Pitavastatin can be increased when it is 
combined with caffeine. 
d)cyclosporine 
 
The serum concentratin of Pitavastatin can be decreased when it is 
combined with cyclosporine. 
e) Lopinavir/Ritonavir 
 
The metabolisam of Pitavastatin can be decreased when combine 
with lopinavir. 
 
f) Erythromycin 
 
Erythromycin significantly increased Pitavastatin exposure. In 
patients taking erythromycin, a dose of Pitavastatin 1mg once daily should not 
be exceeded. 
g) Rifampin 
 
Rifampin significantly increased pitavstatin exposure.In patients taking 
rifampin, a dose of Pitavastatin once daily should not be exceeded. 
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h) Fibrates 
 
It is known that the risk of myopathy during treatment with HMG-CoA 
reductase inhibitors may be increased with concurrent administration of 
fibtrates, pitavstatin should be administrated with caution when used 
concomitantly with gemfibrozil or other fibrates. 
i) Lovastatin 
 
The serum concentration of pitavstatin can be increased when it is 
combine with Lovastatin. 
j) Niacin 
 
The risk of skeletal muscle effects may be enhanced when Pitavastatin 
is used in combination with niacin;a reduction in Pitavastatin dosage should 
be considered in this setting. 
k) Warfarin 
 
Pitavastatin had no significant pharmacokinetic interaction with R-
ans S- warfarin. Pitavstatin had no significant effcet on prothrombin 
time(PT) and international normalized ratio when administered to patients 
receiving chronic warfarin. However, patients receiving warfarin should 
have their PT and INR monitored when Pitavastatin is added to their 
theraphy. 
 FOOD INTERACTION  
          Do not take with red yeast rice. It may increase the risk of myopathy of 
Pitavastatin via pharmacokinetic synergism. Red yeast rice contain 
monocolin k. (similar to lovastatin) 
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OVER DOSE 
There is no known specific treatment in the event of over dose of 
Pitavastatin.in the event of over dose, the patient should be treated 
symptomatically and supportive measures instituted as required. Hemolysis 
is unlikely to be of benefit due to high protein binding ratio of Pitavastatin. 
 
BRAND NAME 
 
Livazo(coated tablets) Livalo (flim coatessd tablets) 
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CHAPTER –VIII 
EXCIPIENTS PROFILE 
1. OLEIC ACID 
SYNONYM: 
1. 9 Octadecenoic Acid 
2. 9-Octadecenoic Acid 
3. cis 9 Octadecenoic Acid 
4. cis-9-Octadecenoic Acid 
5. Oleate 
6. Oleic Acid 
STRUCTURE:  
 
EMPIRICAL FORMULA :  C18H34O2 
MOLECULAR WEIGHT :      282.47g/mol 
DESCRIPTION: 
• Colour :  colourless to pale yellowish 
• Odour :  Odourless 
• Taste  : Peculiar lard-like taste 
•  Solubility :  Insoluble in water; soluble in ethanol, ether, acetone,  
chloroform, dimethyl formamide and dimethyl sulfoxide 
• Meltilng point : 13 to 14oC 
• Viscosity     : 25.6 cp at 30oC 
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• Density : 0.89g/mL at 25oC 
• Refractive index : 1.377   
FUNCTIONAL CATEGORY:  
• Emulsifying agent; 
• Skin penetrant       
SAFETY:   
    Oleic acid is used in oral and topical pharmaceutical formulations. 
 
2. CAPRYOL 90 
SYNONYM: 
  Propylene glycol monocaprylate 90% 
MOLECULAR FORMULA:  
 C11H22O3 
MOLECULAR WEIGHT:   
202.29 
STRUCTURE : 
                   
DESCRIPTION: 
• Colour    : Colourless oily liquid 
• Taste       : Bitter taste. 
• Odour     : Faint 
• Solubility : miscible with ethanol and organic solvents.  
In soluble in   water. 
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• HLB value    : 6 
• Saponification value  : 270-290mg KOH/g  
FUNCTIONAL CATEGORY: 
• Bioavailability enhancer 
• Solubiliser 
• Penetration enhancer 
• Surfactant in Microemulsion. 
3. SESAME OIL 
SYNONYM:  
Sextra;  
Sesame oil,  
Gingilli oil. 
DESCRIPTION: 
• Colour      : a pale yellow liquid  
• Taste         : Pleasant taste 
• Odour       : Pleasant grain like odour. 
• Solubility   : Soluble in chloroform 
• Melting point : -50oC  
• Density   :  0.919 
• Refractive index : 1.47-1.746 
FUNCTIONAL CATEGORY: 
• Used as an ayurvedic medicine as a massaging agent 
• In food preparation. 
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4. SUNFLOWER OIL 
SYNONYM      :   
Sunflower oil 
           Sunflower seed oil 
STRUCTURE: 
 
DESCRIPTION: 
• Colour      : Yellow color viscous liquid 
• Taste            : Pleasant taste. 
• Odour             : Pleasant odour 
• Solubility       : Insoluble in water. Miscible with  
organic solvents. 
• Flash  point   :   >1100 C 
• Viscosity   :  0.04914 kg/m 
• Density   :  918.8 kg/m 
• Refractive index   :  1.4735 
 FUNCTIONAL CATEGORY:       
• In food preparation 
• Dietary supplement 
• Fuel to run engines 
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5. CASTOR OIL 
SYNONYM:  
Ricinus oil, 
cotton seed oil. 
MOLECULAR FORMULA :  C57H104O9 
MOLECULAR WEIGHT :  933.45g/mol 
STRUCTURE: 
                  
DESCRIPTION: 
• Colour       : Colourless to pale yellowish viscous liquid 
• Taste         : Nauseating taste 
• Odour       : Nauseating odour 
• Solubility   : Insoluble in water. Miscible with ethanol 
• Boiling  point : 313oC 
• Viscosity   : 1000 mPa at 20oC 
• Saponification value : 128.6 
• Density   : 961kg/m3 
FUNCTIONAL CATEGORY:  
• Emolient,  
• oleaginous vehicle,  
• solvent. 
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6. TWEEN 80 
SYNONYM  :    
Polysorbate 80 
MOLECULAR FORMULA:  C64H124O26 
MOLECULAR WEIGHT:  1310 
STRUCTURE: 
                                 
DESCRIPTION: 
• Colour    :  Colourless to pale yellow colour  
• Taste       :  Bitter taste. 
• Odour     :  Characteristic odour 
• Solubility : very soluble in water, soluble in ethanol, methanol, toluene 
• Viscosity :   425mPa at 25oC 
• HLB value  : 15 
• Density : 1.06-1.09g/ml 
FUNCTIONAL CATEGORY:  
• Dispesing agent;  
• emulsifying agent;  
• nonionic surfactant;  
• solubilising agent;  
• suspending agent; 
•  wetting agent. 
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7. CREMOPHOR RH 40 
Chemical name  :  Polyoxyl 40 hydrogenated  
• Colour     :  White to yellowish thin paste. 
• Taste        :  Very faint odour 
• Odour     :  Very faint taste 
• Solubility  :  Soluble in water, ethanol, 2-propanol, n-propanol,  
ethyl acetate chloroform, carbon tetra chloride, and 
toluene. 
• HLB value   :  14-16 
• Saponification value :  50-60 
METHOD OF MANUFACTURING:  Reacting hydrogenated castor oil  
with ethylene oxide. 
FUNCTIONAL CATEGORY:  
Solubilizers, 
  In perfume compositions. 
 
8. POLYETHYLENE GLYCOL 400 
SYNONYM:  
Carbowax;  
Carbowax Sentry;  
Lipoxol;  
Lutrol E;  
macrogola;  
PEG;  
Pluriol E and  
polyoxyethylene glycol. 
CHAPTER VIII                                                             EXCIPIENTS PROFILE 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.                   76 
 
MOLECULAR FORMULA: HOCH2 (CH2OCH2)8.7CH2OH 
MOLECULAR WEIGHT: 380-420 g/mol 
DESCRIPTION: 
• Colour     : Colorless liquid 
• Taste        : Bitter 
• Odour      : Charaticcteric 
• Solubility : Soluble in water, Acetone, Alcohols, Benzene, Glycerin. 
• Viscosity  : 105-130 mPas 
• HLB value   : 16 
• Density  : 1.120 
INCOMPATIBILITIES: 
The chemical reactivity of polyethylene glycols is mainly confined to the 
two terminal hydroxyl groups, which can be either esterified or etherified. 
However, all grades can exhibit some oxidizing activity owing to the presence 
of peroxide impurities and secondary products formed by autoxidation. Liquid 
and solid polyethylene glycol grades may be incompatible with some coloring 
agents. 
STABILITY AND STORAGE: 
Polyethylene glycols are chemically stable in air and in solution, although 
grades with a molecular weight less than 2000 are hygroscopic. Polyethylene 
glycols do not support microbial growth, and they do not become rancid. 
Polyethylene glycols and aqueous polyethylene glycol solutions can be 
sterilized by autoclaving, filtration, or gamma irradiation. 
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9.PROPYLENE GLYCOL 
SYNONYM: 
Ethanediol,  
Ethylene glycol 
MOLECULAR FORMULA: C3H8O2 
MOLECULAR WEIGHT: 76.10 g/mol 
STRUCTURE:  
                    
DESCRIPTION:  
• Colour     : Viscous colourless liquid 
• Taste        : Sweet Taste. 
• Odour      : Faint odour 
• Solubility  : Miscible with Acetone, Chloroform, Water,  
ethanol and diethyl ether. 
• Melting point: -59oC 
• Viscosity  :  0.042 Pas 
• HLB value   : 3.4 
• Density  : 1.036g/cm3 
• Refractive index: 1.4399  
FUNCTIONAL CATEGORY: 
Stabilizer,  
Solvent, 
 Humectant 
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10. MICROCRYSTALLINE CELLULOSE 
STRUCTURE 
 
 
SYNONYM: 
Avicel PH; Cellets; Celex; cellulose gel; hellulosum microcristallinum; 
Celphere; Ceolus KG; crystalline cellulose; E460; Emcocel Ethispheres; 
Fibrocel; MCC Sanaq; Pharmacel; Tabulose; Vivapur. 
Empirical Formula: (C6H10O5)n 
Molecular weight: 36000g/mol 
FUNCTIONAL CATEGORY: 
Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrates. 
DESCRIPTION: 
Microcrystalline cellulose is a purified, partially depolymerized cellulose 
that occurs as a white, odorless, tasteless, crystalline powder composed of 
porous particles. 
SOLUBILITY: 
Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents. 
PH: 
pH 5.0-7.5 
 
CHAPTER VIII                                                             EXCIPIENTS PROFILE 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI.                   79 
 
MELTING POINT: 
Chars at 260–2708C. 
INCOMPATIBILITIES: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
STABILITY & STORAGE CONDITION: 
Microcrystalline cellulose is a stable though hygroscopic material. The 
bulk material should be stored in a well-closed container in a cool, dry place.  
HANDLING PRECAUTION: 
Microcrystalline cellulose may be irritant to the eyes. Gloves, eye 
protection, and a dust mask are recommended 
APPLICATIONS: 
1. Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
a binder/diluent in oral tablet and capsule formulations where it is used 
in both wet-granulation and direct-compression Processes. 
2. In addition to its use as a binder/diluent, microcrystalline cellulose also 
has some lubricant and disintegrates properties that make it useful in 
tableting. 
3. Microcrystalline cellulose is also used in cosmetics and food products; 
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CHAPTER IX 
EXPERIMENTAL PROTOCAL 
 
Preformulation study: 
     Preformulation study is the process of optimizing the delivery of drug 
through determination of physicochemical properties of the new compound 
that could affect drug performance and development of an efficacious, stable 
and safe dosage forms, first preformulation studies were performed. Various 
preformulation studies which were carried out are discussed in following 
sections. 
IDENTIFICATION: 
1. Determination of melting point: 
Melting point of Pitavastatin was determined by using open capillary tube 
method in digital melting ploint apparatus. 
Method: 
In this method the capillary tube was sealed with gentle heating from 
one end. Then the small quantity of Pitavastatin was filled into the sealed 
capillary. Capillary existed tied to the tube containing the oil phase in such a 
way that the sealed part of the capillary containing Pitavastatin was dipped 
into the oil. Gently the oil bath was heated. As soon as the powder starts 
melting, the heating was stopped and the temperature was note down. 
2. Solubility of Pitavastatin: 
  Solubility of Pitavastatin was determined in various medias like ethanol, 
methanol, Dichloromethane, Dimethylsulfoxide, 6.8 phosphate buffer etc. 
3. Drug-Excipients Compatibility studies : 
    A proper design and formulation of dosage form require consideration 
of physical, chemical and biological characteristics of both drug and excipients 
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used in formulation of the product. Compatibility must be established between 
active drug and other excipients to produce a stable, efficacious, attractive 
and safe product. Hence before producing the actual formulation compatibility 
of drug with different excipients was tested using the FTIR and DSC 
techniques. 
Fourier Transmittance Infra-Red (FTIR): 
In order to check the integrity (compatibility) of the drug in the 
formulations FTIR spectra of formulations along with the pure drug and other 
excipients were obtained and compared using shimadzu FTIR 
spectrophotometer. In the present study potassium bromide (KBr) pellet 
method was employed. The samples were thoroughly blended with dry 
powdered KBr crystals. The mixture was compressed to form a disc. The disc 
was placed in spectrophotometer and spectrum was recorded. 
Differential scanning Calorimetry (DSC): 
Differential scanning calorimeter or DSC is a thermo analytical 
technique in which difference in the amount of heat required to increase the 
temperature of a sample and reference are measured as a function of 
temperature. Both the sample and reference mentioned at nearly sample 
temperature throughout the experiment. 
Method: 
Accurately weighed Pitavastatin was analyzed by using an automatic 
thermal analyzer system (DSC60 Shimadzu Corporation, Japan0. Sealed and 
perforated aluminium pans were used in this experiment for all the samples. 
Temperature calibrations were performed using indium as standard. An empty 
pan sealed in the same way as for the sample was used as a reference. The 
entire samples were run at a scanning rate of 10oC/min from 50o-300oC. 
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4. STANDARD CURVES FOR PITAVASTATIN 
Phosphate buffer pH 6.8 ( Indian pharmacopoeia 2017) 
A known volume (50 ml) of 0.2 M potassium dihydrogen phosphate is 
placed in a 200 ml volumetric flask. 22.4 ml of 0.2M sodium hydroxide is 
added and makeup to the volume with distilled water. 
0.2M potassium di hydrogen phosphate: 
A known quantity (27.218g) of potassium di hydrogen phosphate is 
dissolved and diluted to 1000 ml with water. 
0.2 M sodium hydroxide: 
A known quantity (8 g) of sodium hydroxide is dissolved and makeup to 
1000 ml with water. 
Determination of λmax : 
            Standard stock solution containing Pitavastatin was prepared by 
dissolving 100 mg of Pitavastatin in 10 ml of Dimethyl sulphoxide in 100 ml 
volumetric flask to dissolve the drug. Then the volume was made up to 100 ml 
using phosphate buffer of pH 6.8 to obtain a concentration of 100μg/ml. the 
stock solution is further diluted using a phosphate buffer pH (6.8) to prepare 
10 μg/ml concentration. The resultant solution was scanned in the range of 
200-400 nm in UV spectrophotometer (UV -1700 shimadzu Corporation, 
Japan) to get absorption maximum (λmax) using phosphate buffer as blank. 
The wave length of maximum absorbance considered for further studies. 
Preparation of standard curves: 
             From the above prepared stock solution, solutions containing 2 to              
10 μg/ml concentrations were prepared using the phosphate buffer pH 6.8 
solution. The absorbance of these solutions are measured at λmax  by              
UV-spectophotometer (UV-1700Sshimadzu corporation Japan). A standard 
curve is plotted using concentration on x-axis and the absorbance obtained on                
Y-axis.  
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5. FORMULATION OF PITAVASTATIN SELF MICRO EMULSION: 
  The SMEDDS of Pitavastatin were prepared by simple admixing 
method. The preparation process involves following steps. 
I. Determination of solubility of Pitavastatin in various vehicles.(oil, 
surfactant, and co-surfactant. 
II.  Selection of oil, surfactant and co-surfactant based on the 
solubility and % transmittance. 
III. Construction of pseudo ternary phase diagram. 
IV. Formulation of  SMEDDS by dissolving the drug in a mixture of 
oil, surfactant and co-surfactant. 
Determination of solubility of Pitavastatin: 
Solubility of Pitavastatin in various oils (Capryol 90, oleic acid, castor 
oil, sesame oil, castor oil), surfactants (tween 20, tween 60, tween  80, 
cremophor RH, span 80), co-surfactant (Propylene glycol, poly ethylene glycol 
400) was determined by dissolving an excess amount of Pitavastatin in 2 ml 
of each of selected oils, surfactant and co-surfactant in stoppered vials. The 
mixtures were continuously stirred using vortex mixer for 10 min and kept at 
37o C±0.5o C in water bath shaker for 78 hours to attain equilibrium. The 
equilibrated samples were centrifuged (3000 rpm for 15 mins) and 
supernatant was filtered through 0.45 μm membrane filter and diluted with 
suitable solvent. Drug content was quantified by using ultraviolet - visible 
(UV_VIS) spectrophotometer. 
Screening of surfactant: 
In order to find appropriate surfactant with good solubilising capacity, 
an emulsifying ability of different surfactants (tween 20, tween 60, tween 80, 
cremophore RH, and span 80) with the screened oil was investigated. 300 mg 
of oil phase and 300 mg of surfactant were weighed and vortexed for two 
minutes followed by warming at 40- 45 C for 30 seconds. So we can obtain an 
isotropic mixture. 50 mg of isotropic mixture was taken and diluted with double 
distilled water previously filtered through 0.45µm membrane filter in a 
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volumetric flask. Number of flask inversions was observed visually to form a 
clear emulsion. The resulting emulsions allowed standing for 2 hours after that 
transmittance were observed at 638 nm. The surfactant which forms a clear 
emulsion with lesser number of inversions and with more transmittance was 
selected. 
Screening of co-surfactant: 
In order to find appropriate co- surfactant with good solubilising 
capacity, after screening of an oil emulsifying ability of different co- surfactants 
(Propylene glycol, poly ethylene glycol 400) with the screened oil was 
investigated. 300 mg of oil phase and 300 mg of surfactant were weighed and 
vortexed for two minutes followed by warming at 40- 45 C for 30 seconds. So 
we can obtain an isotropic mixture. 50 mg of isotropic mixture was taken and 
diluted with double distilled water previously filtered through 0.45µm 
membrane filter in a volumetric flask. Number of flask inversions was 
observed visually to form a clear emulsion. The resulting emulsions allowed 
standing for 2 hours after that transmittance were observed at 638 nm. The 
co- surfactant which forms a clear emulsion with lesser number of inversions 
and with more transmittance was selected. 
Construction of pseudo ternary phase diagram: 
        Phase diagrams are constructed to obtain the proportion of 
components that can result in maximum microemulsion existence area. These 
diagrams were constructed with oil, surfactant/co-surfactant and water using 
water titration method at room temperature. The procedure consisted of 
preparing solutions of different ratio of surfactant to co-surfactant by weight 
such as 1:1, 2:1, 3:1, etc, these solutions then vortexed for 5 mins and placed 
at 50o C for one hour, so that an isotropic mixture was obtained. Each of these 
solutions were used for preparing a mixture containing oil and Smix (mixture of 
surfactant and co-surfactant) in the following ratios by weight, 1:9, 2:8, 3:7, 
4:6, 5:5, 6:4, 7:3, 8:2, 9:1 and after preparation vortexed for 5 mins followed 
by placing in oven at 50o C for one hour. All the mixtures were then placed at 
room temperature for 24 hour. Water from 5 % to 95 % of the mixtures was 
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observed for their appearance (turbid or clear). Turbidity of the samples would 
indicate formation of a coarse emulsion, whereas clear isotropic solution 
would indicate the formation of micro emulsion. Percentage of oil, Smix, water 
at which clear mixture was formed was selected and the values were used to 
construct ternary phase diagram. 
FORMULATION OF LIQUID SMEDDS: 
      From the ternary phase diagram ratio of surfactant to co-surfactant 
was optimized. Then by varying ratio of oil to Smix, different formulations were 
prepared. Formulations were prepared by preparing optimized ratio of Smix 
first, for this surfactant and co-surfactant were accurately weighed and then 
vortexed for 5-10 mints. After that Smix was placed in oven at 500 C for one 
hour. Oil with different ratio was added to Smix. Then these formulations were 
vortexed for 5-10 mints and placed in oven at 50o C for one hour so that an 
isotropic mixture was formed. Drug was loaded to these isotropic mixtures at 
the end and vortexed by vortex shaker until clear solution was obtained. 
CHARACTERIZATION OF LIQUID SMEDDS: 
Visual assessment 
     Pitavastatin liquid SMEDDS was diluted with purified water (100 ml) 
and gently stirred with magnetic stirrer. Temperature should be 370 C. 
Dispersibility test  
The dispersibility test of  SMEDDS was carried out to acssess to 
compatibility to disperse into emulsion and the size of resulting globules to 
categorize them as SMEDDS. It was carried by using a standard USP  paddle 
typw dissolution test apparatus, formulation was added to 500 ml of water at 
37 0.5 C and the paddle was rotated at 50 rpm. On titration with water the 
SMEDDS formulation forms a mixture which was of different type. Depending 
upon which the in vitro performance of formulation can be assessed. 
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S. 
no 
Dispersibility and 
appearance 
Grade 
Time to self 
emulsify 
(minutes) 
1 Rapidly forming (within 1 min) 
Nano or microemulsion having 
a clear or bluish appearance. 
A Within 1 
2 Rapidly forming, slightly clear 
emulsion having a bluish white 
appearance 
B Within 1 
3 Fine milky emulsion that 
formed within 2 minutes. 
C Within 2 
 
 
4 Dull, grayish white emulsion 
having slightly oily appearance 
that is slow to emulsify (longer 
than 2 mints). 
D Within 3 
5 Exhibit poor or minimal with 
large oil droplets presents on 
the surface. 
E Within 3 
 
Determination of self-emulsification time: 
         The emulsification time of SMEDDS was determined according to 
Chinese pharmacopoeia (2005 version), dissolution apparatus. One ml of 
each formulation was added drop wise to 500 ml distilled water at 37±0.5o C. 
Gentle agitation was provided by a standard stainless steel dissolution paddle 
rotating at 50 rpm. Emulsification time assessed visually. 
Thermodynamic stability studies: 
The physical stability of a lipid formulation is very important for its 
performance as its can be adversely affected by precipitation of drug in 
excipient matrix. Poor physical stability of formulation can lead to phase 
separation of excipients which affects bioavailability as well as therapeutic 
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efficiency. Also the incompatibilities between formulation and shell of capsule 
may cause brittleness, softness, and deleted disintegration or incomplete 
release of drug. The following cycles was carried out for these studies. 
Heating cooling cycle 
    The optimized SMEDDS formulations were diluted with 100 times 
distilled water. Six cycles between cooling temperature (4oC) and heating 
temperature (45o C) with exposure at each temperature for not less than 48 
hours were carried. That formulation, which was stable, then was subjected to 
centrifugation test. 
 Centrifugation 
     In order to estimate metastable systems, the optimized SMEDDS 
formulations were diluted with 100 times distilled water. Which pass heating-
cooling cycles are centrifuged at 3500 rpm for 30 mints. Those formulations 
that does not show any phase separation are taken for the freeze thaw stress 
test. 
Freeze thaw cycle 
     This test was performed for accelerated stability testing of Nano 
emulsion formulation. In this study three freez thaw cycle of formulations were 
exposed between temperatures 21o C-25o C for each temperature cycles not 
more than 48 hours. For the better estimation of accelerated stability studies 
six such cycles should be run for each batch of formulation. The formulations 
which showed the maximum stability were selected for further study. 
Cloud point measurement: 
     Dilute the formulation 1 ml with 1000 ml of water in beaker and placed on a 
water bath with gradually increasing the temperature until the diluted 
formulation turned to cloudy or turbid. It gives the information about the 
stability of the micro emulsion at body temperature. 
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Robustness to dilution: 
       Robustness to dilution was studied by diluting SMEDDS to 50, 100, 
1000 times with water, phosphate buffer pH 6.8, phosphate buffer pH 7.4. The 
diluted SMEDDS were stored for 12 hour and observed for any signs of phase 
separation or drug precipitation. 
 Refractive index and percent transmittance: 
    Refractive index and percent transmittance proved the transparency of 
formulation. The refractive index measured using Abbes refractometer. The 
percent transmittance of the system is measured at particular wavelength 
using UV-spectrophotometer keeping distilled water as blank. Stability of 
micro emulsion formulation with respect to dilution is checked by diluting one 
ml of formulation with 100 ml of distilled water and measuring transmittance 
using U.V. Spectrophotometer. Transmittance of samples is measured at 638 
nm and for each sample three replicate assays are performed. 
Viscosity determination: 
      The rheological properties of the micro emulsion are evaluated by 
Ostwald visco meter. These viscosity determinations confirm whether the 
system is w\o or o\w. If system has low viscosity, then it is o/w type of the 
system and if high viscosities then it are w\o type of the system. 
Absolute drug content in L-SMEDDS: 
       Liquid SMEDDS containing Pitavastatin, equivalent to 4 mg was diluted 
in suitable quantity of methanol. The sample was mixed thoroughly to dissolve 
the drug in methanol by stirring. The solvent extract is filtered through 0.45 µm 
membrane filter. Drug content was determined by measuring the absorbance 
in UV spectro photometer against the standard solvent solution of drug. 
Conversion of liquid SMEDDS into solid S-SMEDDS: 
Solid SMEDDS were prepared by mixing liquid SMEDDS containing 
Pitavastatin with microcrystalline cellulose (MCC) in 1:1 proportion. Liquid 
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SMEDDS was added drop wise over MCC and homogenized using glass rod 
to ensure uniform distribution of formulation in a china dish. 
Physiochemical characterization of SMEDDS: 
Micromeritic properties: 
      Prepared solid- SMEDDS was evaluated for micromeritic properties 
such as angle of repose, bulk density and tapped density, compressibility 
index and Hausner’s ratio. 
a) Angle of Repose 
 Angle of Repose is defined as the maximum angle possible between 
the surface of the pile of powder and horizontal plane. Angle of repose has 
been used as indirect methods of quantifying powder flow ability, because of 
their relationship with inter particle cohesion. A static heap will slide when the 
angle of inclination is large enough to overcome frictional forces and stop 
when gravitational forces balance the forces. The sides of heap will make an 
angle with horizontal which is called angle of repose. (Satyabrata Bhanja et 
al., 2013) 
Angle of Repose (ø) = tan -1 (h / r) 
 
Where,   h = height of the heap, 
 
r = radius of the heap 
TABLE 2: 
 
Angle of Repose  Type of Flow 
<20 Excellent 
20 – 30 Good 
30 – 35 Moderate 
35 – 40 Poor 
>40 Very Poor 
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b) Bulk Density: 
                Bulk density denotes the total density of the material. It includes the 
true volume of interparticle spaces and intraparticle pores. The packing of 
particles is mainly responsible for bulk. Bulk density is the ratio between a 
given mass of powder and its bulk volume. Apparent bulk density is determined 
by pouring the weighed granules into a graduated cylinder via funnel and 
measuring the volume. Density is calculated by using the formula, 
(SatyabrataBhanjaal.,2013 ) 
 
                        Bulk density    =     weight of the powder      = W 
                                                  Bulk volume of the powder     Vo 
 
c) Tapped Density: 
           A known quantity of sample is transferred to a graduated cylinder 
and placed on tapped density apparatus and operated for a fixed number 
of taps (100).It is the ratio of weight of sample to tapped 
volume.(Satyabrata Bhanja et al., 2013) 
 
                       Tapped density  =     Weight of the powder (W) 
                                                        Tapped volume of powder Vf 
 
d) Compressibility (or) Carr’s index: 
Based on the apparent bulk density and the tapped density, the 
percentage compressibility of the bulk drug is studied by using the 
following formula. 
 
                                  Carr’s index (%) =   Tapped density - bulk density × 100 
                                                                         Tapped density 
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   TABLE 3: 
 
Compressibility Index (%) Type of Flow 
5-15% Excellent 
15-25% Good 
>25% Extremely poor 
 
e)  Hausner's ratio: 
Hausner’s ratio is defined as the ratio of tapped density to bulk 
density of the powders. The Hausner’s ratio is a number that is correlated 
to the flowability of a powder (or) granular material. It is calculated by 
using the formula, 
    
Tapped density 
 
Hausner 's  ratio       =   
          Bulk density 
 
Where,   
             o= Bulk density g/ml. 
               t = Tapped density g/ml. 
 
The values less than 1.25 indicate good flow (=20% Carr), whereas 
greater than 1.25 indicates poor flow (=33% Carr) Between 1.25 and 1.5, 
added glidant normally improves flow. (SatyabrataBhanja et al,2013) 
 Drug content:   
The S-SMEDDS containing Pitavastatin, equivalent to 4 mg was diluted 
in suitable quantity of methanol and sonicated for 10-15 mints. Then it was 
filtered through 0.45μm membrane filter. Drug content was analyzed by 
measuring absorbance using UV spectrophotometer. 
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Invitro drug release from S-SMEDDS: 
       The in vitro drug release of prepared S-SMEDDS was assessed in 
triplicate using United States Pharmacopoeia (USP) Dissolution Type II 
apparatus (Paddle type) at 37±0.5o C. S-SMEDDS containing 4 mg equivalent 
of drug was placed in 900 ml of dissolution medium ( phosphate buffer pH 
6.8with methanol in 9:1 ratio). The revolution speed of the paddle was 
maintained at 100 rpm. At predetermined time intervals, 5 ml of dissolution 
medium was collected, filtered and the same volume of fresh dissolution 
medium was replenished to maintain the sink conditions. The samples were 
analyzed for the drug concentration using UV-VIS spectrophotometer at 245 
nm 
f) Release Kinetics: 
The results of in vitro release profiles obtained for all the formulations 
were fitted into five models of data treatment as follows: 
1. Cumulative percent drug released versus time (zero-order kinetic model). 
2. Log cumulative percent drug remaining versus time. (First-order kinetic 
model). 
3. Cumulative percent drug released versus square root of time (Higuchi’s 
model). 
4. Log cumulative percent drug released versus log time (Korsmeyer-
Peppasequation). 
5. Cumulative percent drug released versus cube root of time 
(Hixson and Crowell’scubic root law of dissolution) 
Zero Order Kinetics A zero-order releases would be predicted by the 
following equation. 
At = A0 – K0t…………………………………….(6) 
Where: 
            At = Drug release at time‘t’ 
           A0 = Initial drug concentration 
            K0  = Zero-order rate constant (hr) 
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    When the data is plotted as cumulative percent drug release versus 
time, if the plot is linear then the data obeys zero-order release kinetics, 
with a slope equal to K0. 
 
1) First Order Kinetics: A first-order release would be predicted by 
the following equation 
Log C = Log C0 – 303.2Kt……………………….. (7) 
Where: 
                    C = Amount of drug remained at time ‘t’ 
                    C0= Initial amount of drug. 
                   K = First-order rate constant (hr). 
 
When the data are plotted as a log of percent cumulative drug release 
remaining versus time yields a straight line, indicating that the release follows 
First-order kinetics. 
The constant ‘K’ can be obtained by multiplying 2.303 with slope values. 
2.Higuchi’s Model 
  Drug released from the matrix devices by diffusion has been described 
by following Higuchi’s classical diffusion equation. 
 
1/2 ……………………. (8) 
Where, 
 
Q = Amount of drug released at time‘t’ 
              D = Diffusion coefficient of the drug in the matrix 
              A = Total amount of drug in unit volume of matrix  
  CS = The solubility of the drug in the diffusion medium 
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ε = Porosity of the matrix τ = Tortuosity t = Time (hrs) at which ‘Q’ 
amount of drug is released. 
Equation-8 may be simplified if one assumes that D, CS and A are 
constant. Then equation-8 becomes: 
Q = Kt½ ………………………….. (9) 
When the data is plotted according to equation-4 i.e., cumulative drug 
released versus square root of time, yields a straight line, indicating that 
the drug was released by diffusion mechanism. The slope is equal to ‘K’. 
 
3) Korsmeyer and Peppas Model 
 
The release rates from controlled release polymeric matrices can be 
described by the equation (10) proposed by korsmeyer et al. 
 n Q = K1t ………………………………. (10) 
Q is the percentage of drug released at time‘t’, K is a kinetic 
constant incorporating structural and geometric characteristics of the 
tablets and ‘n’ is the diffusional exponent indicative of the release 
mechanism. 
 
4) Hixson and Crowell’s cubic root law of dissolution 
The Noyes-Whitney’s equation assumes that surface area of the 
dissolving solid remains constant during dissolution, which is practically 
not possible for dissolving particles. Hence, dissolution methods that 
involve use of constant surface area discs are employed to determine the 
rate of dissolution. 
To account for the particle size decrease and change in surface 
area accompanying dissolution, Hixson and Crowell’s cubic root law of 
dissolution is used: 
                                        W0 1/3 – W1/3 = Kt 
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EVALUATION OF BEST FORMULATION: 
a) Infrared (IR) spectroscopic studies: 
            Infrared (IR) spectrum analysisare carried out for the selected  
formulation of Liquid SMEDDS and S-SMEDDS to find out the interactions 
between the drug and excipients by using IR spectrophotometer (Spectrum 
RX-1 Perkin Elmer, German). The pellets are prepared on KBr-press under 
hydraulic pressure of 150kg / cm2; the spectra is scanned over the wave 
number range of 4000 to 400 cm-1 at the ambient temperature (Sinco.C et al., 
2011). 
b) Morphological studies of S-SMEDDS  by using Scanning Electron 
Microscopy (SEM): 
Morphological evaluation of the selected Pitavastatin nanocrystal 
formulation is carried out in scanning electron microscope (SEM) (Hitachi 
X650, Tokyo, Japan). All samples are examined on a brass stub using carbon 
double-sided tape. Powder samples are glued and mounted on metal sample 
plates. The samples are gold coated (thickness ≈15–20 nm) with a sputter 
coater (Fison Instruments, UK) using an electrical potential of 2.0 kV at 25 mA 
for 10 min. An excitation voltage of 20 kV was used in the experiments (Yuan 
Gao et al., 2011). 
c) X-ray Powder Diffraction (XRPD) analysis: 
The crystalline state of the samples, including the drug and freeze-
dried powders are studied in X-ray diffractometer (XRD-462, Digaku, Japan). 
XRPD is carried out in symmetrical reflection mode using Copper line as the 
source of radiation and the wavelength is set at 1.5405A˚. Standard runs 
using a 40 kV and 30 mA in this process. Samples are performed with a 
scanning rate of 0.1000◦/min and the scanning range of the 2 from the initial 
angle 4˚ to the final angle 90˚ (Dianrui Zhang et al., 2011). 
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d) Determination of Particle size and Zeta potential: 
The mean particle size (z-average), and zeta potential of Pitavastatin 
SMEDDS formulations are determined by dynamic light scattering technique 
using a zeta size analyzer (Nano ZS 90, Malvern Instruments Ltd., UK). The 
freeze dried powders are redispersed with water to obtain a proper scattering 
intensity before measurement (Dianrui Zhang et al., 2014). 
e) Differential Scanning Calorimetry:  
Physical state of Pitavastatin in S-SMEDDS was characterized using 
differential scanning calorimeter, thermo grams of Pitavastatin, and S-
SMEDDS were measured in Perkin elmer pyris(Shelton, CT) equipped with an 
intracooler 2P cooler accessory.Samples of 4mg are placed in standard 
aluminium pans and sealed with a lid. 
Heating scans by 100C/min, is applied with a nitrogen purge of 
20ml/min, over a temperature range of 350C to 3800C. An empty aluminium 
pan is used as reference. (Solanki. D.et al., 2013). 
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CHAPTER X 
                                          RESULTS AND DISCUSSION 
1. STANDARD CURVES FOR PITAVASTATIN 
 
a) Preparation of dissolution medium 
The calibration medium was (phosphate buffer and pH 6.8) was 
prepared by as per the I.P procedure (I.P 2014) 
b) Estimation of absorption maximum (λmax) 
 The λmax of Pitavastatin was estimated by scanning the 10μg/ml 
concentration of the drug solution in buffer solution of phosphate buffer pH 
(6.8). It showed the λ max of 245nm (Narendra Chary., et al., 2012) in 
phosphate buffer solution of pH (6.8). The result was shown in table 1 and 
figure 1.  The linear correlation coefficient was found to be 0.9993 for pH (6.8). 
Pitavastatin obeys the Beer’s law within the concentration range of 2 to 10 
µg/ml.  
2. Infrared (IR) spectroscopic studies 
 
Infrared (IR) spectroscopic studies were carried out to confirm the 
compatibility between drug and excipients used for the preparation of 
SMEDDS. The IR studies were performed for pure drug, stabilizers and 
physical mixture of drug with stabilizers. The spectra studied at 4000cm-1 to 
400 cm-1 were shown in (Table 15) and (Figure 2(a)-2(f). The principal peaks 
for pure drug were observed at wave numbers 3066 cm-1, 2958 cm-1,                    
3003 cm-1, 1720 cm-1, 1490 cm-1 and 1219.01 cm-1, 678.94 cm-1.  THE 
results clearly indicated that there was no interaction between the drug and 
excipients and the drug was present in its unchanged form. 
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3. FORMULATION OF PITAVASTATIN SELF MICRO EMULSION: 
  The SMEDDS of Pitavastatin were prepared by simple admixing 
method. The preparation process involves following steps. 
i. Determination of solubility of pitavastatin in various vehicles.(oil, 
surfactant, and co-surfactant. 
ii.  Selection of oil, surfactant and co-surfactant based on the solubility and 
% transmittance. 
iii. Construction of pseudo ternary phase diagram. 
iv. Formulation of SMEDDS by dissolving the drug in a mixture of oil, 
surfactant and co-surfactant. 
Determination of solubility : 
 The components in the formulation of SMEDDS were selected to have 
maximum solubility of Pitavastatin along with good miscibility with each other to 
produce an isotropic and stable system. Solubility of pitavastatin in various 
vehicles was screened and the results are presented in Table 2 and figure 4.  
Pitavastain had significantly higher solubility in oleic acid (97.89±0.081%) and 
capryol 90 (93.69±0.38%) other than castor oil, Sesame oil, sunflower oil. 
Among surfactant and co-surfactants, Tween 80 (90.22±0.37%), Cremophor 
RH (88.73±0.24%), Propylene glycol (93.07±1.26%) showed highest solubility. 
Therefore, oleic acid and Capryol 90 were selected as oil phase based on 
solubility studies.  
Screening of components: 
      Surfactants and co-surfactants are selected based on the % 
Transmittance. Out of various surfactants and co-surfactant screened Tween 
80 revealed (93.52±0.22%), and with oleic acid. And Cremophor RH RH 40 
revealed 97.65±0.28%. Tween 80 and Cremophor RH RH 40 showed the 
highest value amongst all. Hence both are selected for the development of the 
formulation. 
Similarly, in case with co-surfactants Propylene glycol resulted in higher 
% Transmittance value (95.29±0.10% and 97.82±0.27%) for both the oils oleic 
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acid and Capryol 90 respectively. Hence Tween 80 and Cremophor RH RH 40 
were selected as surfactants to form a stable emulsion. And Propylene glycol 
was selected as a co-surfactant. And the results were shown in Table (3) and 
figure 5 (a) & 5 (b). 
Construction of Pseudo ternary phase diagram: 
    The microemulsion region was determined by plotting data in pseudo 
ternary phase diagram. The selected oil, surfactants and co-surfactants were 
used to formulate micro emulsion. Nine different combination of oil and Smix 
were selected to construct phase diagram for two types of formulation (oleic 
acid and Capryol 90). The ratio of Smix was selected as 1:1, 2:1, 3:1. The 
diagrams are depicted in figure (6) and (7). From the figures for the oleic acid 
formulation it showed that Smix ratio of 3:1 (figure 6 c) has more emulsification 
area as compared to Smix ratio of 1:1 and 2:1. And for the Capryol 90 
formulation Smix ration of 2:1 (figure 7 b) have more emulsification area as 
compared to 1:1 and 3:1. Hence for the formulation of SMEDDS the ratio of 
surfactant mixture was kept as 3:1 for oleic acid formulation and 2:1 for the 
Capryol 90 formulation. 
FORMULATION OF LIQUID SMEDDS: 
 Based on the pseudoternary phase diagrams, the formulation with the 
best self-emulsifying properties, containing oleic acid (10-50%) with Smix of 
Tween 80 and Propylene glycol (50-90%), and Capryol 90 (10-50%) with S of 
Cremophor RH RH 40 and Propylene glycol (50-90%) were formulated with 
varying ratios of oil, surfactatnt and co-surfactant as shown in Table 4 (a), 4 
(b). 
CHARACTERIZATION OF LIQUID SMEDDS: 
Dispersibility test and Visual assessment 
   Pitavastatin liquid SMEDDS was diluted with purified water (100 ml) and 
gently stirred with magnetic stirrer. Temperature should be 370 C. The results 
represented in Table 5(a) & 5(b). 
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Visual assessment of liquid SMEDDS formulation 
Thermodynamic stability studies: 
SMEDDS are thermodynamically stable systems and are formed at a 
particular concentration of oil, surfactant and water, with no phase separation, 
creaming or cracking. It is the thermostability which differentiates nano or 
microemulsion from emulsions that have kinetic stability and will eventually 
phase separate. Thus, the formulations were subjected to different 
thermodynamic stability by using heating cooling cycle, centrifugation and 
freeze thaw cycle stress tests. Those formulations, which survived 
thermodynamic stability tests, were taken for further studies. It was observed 
that formulation OF3 ,OF5, OF6, CF3 and CF6 did not pass the thermodynamic 
stress tests and thus were dropped for further study .The results are as shown 
in Table 6 (a), 6(b). 
 
Cloud point measurement: 
     Dilute the formulation 1 ml with 1000 ml of water in beaker and placed on 
a water bath with gradually increasing the temperature until the diluted 
formulation turned to cloudy or turbid. It gives the information about the stability 
of the micro emulsion at body temperature. The results are represented in 
table 7. The cloud point of all the SMEDDS except OF3, OF5, OF6, CF3, CF5 
and CF6 was found to be higher than 85oC, which indicates that micro emulsion 
will be stable at physiological temperature without risk of phase separation. 
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Formulations OF3, OF5, OF6, CF3, CF5 and CF6 shows phase separation due 
to precipitation of drug. So these cannot be considered as the good 
formulations due to phase separation at higher temperature 
Robustness to dilution: 
After diluting SMEDDS to 50, 100 and 1000 times with water, buffer pH 
7.4 and pH 6.8 and storing for 12 h, it was observed that there was no sign of 
phase separation or drug precipitation in formulations except OF3, OF5, OF6, 
CF3, CF5 and CF,  which turned hazy after standing for long hours. Hence, 
formulations OF3, OF5, OF6, CF3, CF5 and CF6 were rejected as they were 
also showing phase separation and became hazy on dilution. The results were 
shown in Table 8 (a) and 8 (b). 
Refractive index and percent transmittance: 
Refractive Index and percent transmittance are determined to check the 
transparency of formulation. Refractive Index of the formulation is measured by 
refractometer by placing drop of solution on slide and then compare it with 
water (RI=1.333). If refractive index is similar to refractive index of water and 
percentage transmittance above 90%, then formulations have a transparent 
nature. The results of Refractive index and percentage Transmittance are 
shown in Table 9. Formulation OF6 , OF7 ,OF9, CF1, CF2, CF3, CF4, CF8, 
and CF9 have transmittance value greater than 90%, suggesting their clarity. 
And the refractive index of formulation OF2, OF8, and CF4, CF8, CF9 has the 
values nearest to RI of water. 
Viscosity determination: OF3, OF5, OF6, CF3, CF5 and CF6 were 
rejected due to instability. Remaining formulations were subjected to viscosity 
determination. 
From the viscosity determination it was observed that as the 
concentration of co-surfactant increased viscosity of the formulation also 
increased. So formulation F1-F4 was highly viscous due to higher co-surfactant 
concentration. 
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The concentration of surfactant also increases the viscosity of the 
formulation. It was expected that F5-F9 would show the highest viscosity due to 
high concentration of oil. Out of 18 formulations, CF8 and OF8 (oil-45% and 
Smixture-55%) shown optimum viscosity due to optimum concentration of oil, 
surfactant and co-surfactant. The results were shown in table 10. 
Absolute drug content in L-SMEDDS: 
Drug content was determined by measuring the absorbance in UV 
spectro photometer. The results are in the range of 92.79 %-97.43%. The 
results are represented in Table 11 and figure 8 (a) and 8 (b). From the results, 
formulation OF8 (97.8±0.08%) and CF8 (97.33±0.52%) show the highest drug 
content amongst all the other formulations. 
Conversion of liquid SMEDDS into solid S-SMEDDS: 
Solid SMEDDS were prepared by mixing liquid SMEDDS containing 
pitavastatin with microcrystalline cellulose (MCC) in 1:1 proportion. Liquid 
SMEDDS was added drop wise over MCC and homogenized using glass rod to 
ensure uniform distribution of formulation in a china dish. 
Characterization of S-SMEDDS: 
a) Micromeretic properties: 
Angle of Repose 
Angle of repose for the best formulation (OF8 and CF8) was 26°54’ and 
28o38’ respectively. The results suggested that the powder blend of formulation 
shows good flow properties. The result of angle of repose of best formulation 
was shown in table 12 a & b. 
Bulk density ( gm /ml) 
The bulk density for the best formulations (CF8 & OF8) were 
0.3436±0.006g/ml and 0.3423±0.006g/ml.The results indicated that the powder 
blends of formulation have good flow properties. The results were summarized 
in table12 a & b. 
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Tapped density (gm/ml) 
Tapped density for the best formulation (CF8 & OF8) 0.4043±0.001g/ml 
and 0.404±0.001g/ml respectively. The results indicating the presence of 
smaller particles occupying the voids between the bigger particles. The results 
were summarized in table 12 a & b. 
Carr’s index 
The Carr’s index of the best formulation CF8 & OF8 was found to be 
15.01±0.001% and 15.27±0.001%, which indicated that the powder blend was 
good. The results were summarized in table 12 a & b. 
Hausner’s ratio: 
The Hausner ratio of the best formulation (CF8 & OF8) was found to be 
1.17±0.002 and 1.18±0.002. Since a very low Hausner ratio (<1.25) was 
obtained the formulations showed better property. The results were 
summarized in table 12 a & b. 
Drug content:   
   The drug content of all the S-SMEDDS formulations (OF1-OF9) and 
(C1-CF9) were in the range of 96.54 % to 98.02 %. The results are represented 
in Table 13, & figure 9 (a) & 9 (b) and it suggests that uniform distribution of 
drug in the formulation. Formulation OF8 (98±0.09%) and CF8 (98.02±0.07%) 
show the highest drug content amongst all other formulations. 
In vitro drug release from S-SMEDDS: 
The dissolution study was carried out in phosphate buffer of pH 6.8 for 
two hours. The in vitro dissolution studies of all the formulations were 
compared with pure drug and conventional tablet. The results of in vitro drug 
release studies from Pitavastatin SMEDDS formulation were represented in 
Table 14(a) and 14(b).  
The results suggest that the % release of all the formulations is greater 
than that of the pure drug (59.25%±0.20) and conventional tablet 
(64.72%±0.21).  
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  Formulation CF8 and OF8 shown the highest percentage drug release 
of 82.14±0.15% and 80.52±0.12% at the end of two hours respectively than the 
other formulations.  
SELECTION OF BEST FORMULATION: 
From the above characterization, the two formulations OF9 and CF8 
were selected as the best formulation showing, 
For OF8 
% Transmittance   94.28±0.22    
Refractive index             1.333±0.0004 
Drug content                   98.13±0.09%    
In vitro drug release         80.52±0.12% for two hours            
For CF8 
% Transmittance         95.08±0.16 
Refractive index             1.333±0.0004 
Drug content                98.02±0.07          
In vitro drug release      82.14±0.15         
COMPARISON OF IN VITRO DRUG RELEASE OF BEST 
FORMULATION WITH PURE DRUG AND MARKETED CONVENTIONAL 
TABLET: 
The comparison of in vitro drug release profile of best formulation is 
compared with that of the pure drug and conventional tablet. It represented in 
figure 12. 
 Pure drug                   (59.25%±0.20)  
 Conventional tablet  (64.72%±0.21) 
OF8                             (80.52% ±0.12) 
CF8                              (82.14%±0.15) 
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KINETICS ANALYSIS 
 The in vitro dissolution study results were fitted into 0 order first order 
Higuchi Koresmeyer peppas and Hixson Crowel model to find out the in vitro 
kinetic release studies. The result indicated the the values follow first order 
reaction. 
 According to values of koresmeyer peppas equation which is greater 
than one indicates it follows supercase II transport which means it follows more 
than one mechanism. 
EVALUATION OF BEST FORMULATION: 
a) Infrared (IR) spectroscopic studies: 
Infrared (IR) spectroscopic studies were carried out for pure drug, 
excipients and selected SMEDDS formulations (CF8 and OF8). The spectra 
studied at 4000cm-1 to 400 cm-1 were shown in (Table 15) and (Figure 
18(a)to 18(e)). It was found from the spectra that there was no major shifting as 
well as any loss of functional peaks in the spectra of drug, excipients and 
selected formulations (CF8 & OF8). This clearly indicated that there was no 
interaction between the drug and the polymer and the drug was present in its 
unchanged form. 
b) Morphological studies of S-SMEDDS by using Scanning Electron 
Microscopy (SEM): 
The surface morphology of the pure drug and solid SMEDDS were 
examined by the SEM and the images are represented in figure 19 (a) and 
19(b). The typical crystalline structure of Pitavastatin as shown in figure 19 (a) 
was absent in S-SMEDDS of Pitavastatin, which indicates the transformation of 
the drug from crystalline state tto amorphous state i.e the drug is completely 
solubilised in oil phase of L-SMEDDS. 
c) X-ray Powder Diffraction (XRPD) analysis: 
The PXRD patterns of pure drug (Pitavastatin) and formulations (OF8 & 
CF8) were presented in (Figure 20(a) and 20(b).The XRPD patterns of pure 
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drug showed numerous sharp peaks (at 2θ 15.00°, 16.80°, 20.90°, 23.00°, 
25.40° and 34.31°) which are the characteristic of a crystalline compound. And 
these peaks are absent in the PXRD pattern of SMEDDS indicating the 
transformation crystalline nature to Amorphous nature. 
d) Determination of Particle size and Zeta potential: 
 The results of Particle size, zeta potential and Polydispersibility index of 
the best formulations CF8 and OF8 was shown in figure 21 (a) -21 (d). The 
particle size of the S-SMEDDS was found to be 139.5 nm and 621.3 nm with 
polydispersibility index of 0.291 and 0.377 for OF8 and CF8 respectively. Since 
the value of polydispersibility index is less than 1 indicates uniform distribution 
of droplets throughout the formulation. And the zeta potential values of the best 
formulation were found to be -23.9 and -20.9 for CF8 and OF8 respectively. 
The negative zeta potential indicates the stable formulation. 
e) Differential Scanning Calorimetry:  
Physical state of Pitavastatin in S-SMEDDS was characterized using 
differential scanning calorimeter. The DSC thermogram of S-SMEDDS 
formulation were shown in figure 22. The DSC thermogram of Pitavastatin 
showed a characteristic, sharp endothermic peak at corresponding to its 
melting point (less than 138oC) and it indicates the crystalline nature of the 
drug. The DSC analysis of prepared SMEDDS formulation revealed negligible 
change in the melting point of Pitavastatin in the presence excipients, indicating 
no modification or interaction between the drug and excipients. 
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TABLE 1: CALIBRATION OF PITAVASTATIN CALCIUM USING PHOSPHATE BUFFER OF pH 6.8 
        
 
 
 
 
 
 
                
                                                                                      REGRESSION VALUE: 0.99935±0.0002 
 
 
 
, 
 
 
 
 
 
 
 
 
 
 
S. No Concentration (μg/ml) Absorbance ±SD 
1 1 0.109±0.004 
2 2 0.201±0.009 
3 3 0.282±0.014 
4 4 0.371±0.019 
5 5 0.465±0.008 
6 6 0.557±0.003 
7 7 0.637±0.013
8 8 0.739±0.013
9 9 0.827±0.013
10 10 0.92±0.013
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   TABLE 2: SOLUBILITY OF PITAVASTATIN CALCIUM IN VARIOUS VEHICLES 
S.NO VEHICLE SOLUBILITY (%) 
1 Oleic acid 97.89±0.06 
2 Capryol 90 93.69±0.31 
3 Castor oil 20.44±0.41 
4 Sesame oil 15.61±0.15 
5 Sunflower oil 14.42±0.33 
6 Tween 20 77.02±0.33 
7 Twen 60 51.14±0.13 
8 Tween 80 90.22±0.30 
9 Cremophor RH 40 88.73±0.19 
10 Span 80 30.64±0.15 
11 Propylene glycol 93.07±1.03 
12 Poly ethylene glycol 400 87.61±0.4 
  
TABLE 3: % TRANSMITTANCE VALUES OF SURFACTANTS AND CO SURFAC-
TANTS 
 
 
S.NO COMPONENTS 
% TRANSMITTANCE VALUE 
WITH OLEIC ACID WITH CAPRYOL 90 
1 Tween 20 35.15±0.14 93.72±0.14 
2 Tween 60 40.62±0.25 84.77±0.14 
3 Tween 80 93.52±0.22 87.70±0.28 
4 Cremophor RH40 48.44±0.19 97.65±0.28 
5 Span 80 40.37±0.09 53.78±0.37 
6 PEG 400 93.30±0.17 94.36±0.20 
7 Propylene glycol 95.29±0.10 97.82±0.27 
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TABLE 4 (a):  FORMULATION OF SMEDDS USING OLEIC ACID, TWEEN 80, AND 
PROPYLENE GLYCOL AT THE SMIX RATIO OF 3:1 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FORMULATION 
CODE 
DRUG 
OLEIC AC-
ID 
(%) 
SMIXTURE(TWEEN 
80:PROPYLENE 
GLYCOL)(3:1) 
(%) 
OF1 4 mg 10 90 
OF2 4 mg 15 85 
OF3 4 mg 20 80 
OF4 4 mg 25 75 
OF5 4 mg 30 70 
OF6 4 mg 35 65 
OF7 4 mg 40 60 
OF8 4 mg 45 55 
OF9 4 mg 50 50 
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TABLE 4 (b):  FORMULATION OF SMEDDS USING CAPRYOL 90, CREMO-
PHORE RH AND PROPYLENE GLYCOL AT THE SMIX RATIO OF 2:1. 
 
 
 
 
 
 
 
 
 
 
 
FORMULATION 
CODE 
DRUG 
CAPRYOL 90 
(%) 
SMIXTURE(CREMOPHORE 
RH:PROPYLENE GLY-
COL)(2:1) 
(%) 
   CF1 4 mg 10 90 
CF2 4 mg 15 85 
CF3 4 mg 20 80 
CF4 4 mg 25 75 
CF5 4 mg 30 70 
CF6 4 mg 35 65 
CF7 4 mg 40 60 
CF8 4 mg 45 55 
CF9 4 mg 50 50 
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TABLE 5 (a): DISPERSIBILITY TEST AND VISUAL ASSESSMENT OF SMEDDS FORMULATION 
CODE NO. 
DISPERSIBILITY AND APPEAR-
ANCE 
SE TIME GRADE 
OF1 Clear and Transparent Within 1 mint A 
OF2 Dull Within1 mint C 
OF3 Transparent Within 2 mints B 
OF4 clear Within 1 mint B 
OF5 Dull Within1 mint A 
OF6 Transparent Within 1 mint B 
OF7 Clear Within 3 mints D 
OF8 clear Within 1 mints D 
OF9 clear Within 1 mint A 
 
 
TABLE 5 (b): DISPERSIBILITY TEST AND VISUAL ASSESSMENT OF SMEDDS FORMULATION 
CODE NO. 
DISPERSIBILITY AND APPEAR-
ANCE 
SE TIME GRADE
CF1 Clear and transparent within 1 mint A 
CF2 Clear  within 1 mint A 
CF3 Transparent within 1 mint B 
CF4 Clear within 2 mints A 
CF5 Transparent within 1 mint A 
CF6 Transparent within 2 mints B 
CF7 Dull  within 3 mints D 
CF8 Clear within 1 mint A 
CF9 Turbid within 1 mint E 
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TABLE 6 (a): THERMODYNAMIC STABILITY ASSESSMENT OF OLEIC ACID SMEDDS. 
Formulation 
Heating cooling 
cycle 
Centrifugation freeze thaw cycle 
OF1 √ √ √ 
OF2 √ √ √ 
OF3 × × × 
OF4 √ √ √ 
OF5 × × × 
OF6 × × × 
OF7 √ × × 
OF8 √ √ √ 
OF9 √ √ √ 
√ - Passed    ×-Failed 
 
TABLE 6 (b): THERMODYNAMIC STABILITY ASSESSMENT OF CAPRYOL 90 SMEDDS. 
Formulation 
Heating cooling 
cycle 
Centrifugation Freeze thaw cycle 
CF1 √ √ √ 
CF2 √ √ √ 
CF3 × × × 
CF4 √ √ √ 
CF5 √ √ √ 
CF6 √ √ √ 
CF7 √ √ √ 
CF8 √ √ √ 
CF9 √ √ √ 
√ - Passed    ×-Failed 
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TABLE 7: MEASUREMENT OF CLOUD POINT 
S.NO FORMULATION  CLOUDPOINT 
(0C) 
FORMULATION CLOUD POINT (O C) 
1 OF1 86.5 CF1 85.6 
2 OF2 86 CF2 85 
3 OF3 UNSTABLE CF3 UNSTABLE 
4 OF4 85 CF4 85 
5 OF5 UNSTABLE CF5 UNSTABLE 
6 OF6 UNSTABLE CF6 UNSTABLE 
7 OF7 85 CF7 85 
8 OF8 88 CF8 87 
9 OF9 87 CF9 86 
                          
 
                      TABLE 8 (a): RESULTS OF ROBUSTNESS TO DILUTION 
S.NO MEDIUM 
PHASE SEPARATION 
OF1 OF2 OF3 OF4 OF5 OF6 OF7 OF8 OF9 
1 Distilled water No No No No No No No No No 
2 Phosphate buff-
er pH 6.8pH 
No No No No No yes No No No 
3 Phosphate buff-
er pH7.4 
No No Yes No Yes Yes No No No 
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                      TABLE 8 (b): RESULTS OF ROBUSTNESS TO DILUTION 
S.NO MEDIUM 
PHASE SEPARATION 
CF1 CF2 CF3 CF4 CF5 CF6 CF7 CF8 CF9 
1 Distilled water No No No No No No No No No 
2 
Phosphate buff-
er pH 6.8pH 
No No Yes No No yes No No No 
3 
Phosphate buff-
er pH7.4 
No No Yes No Yes No No No No 
 
 
TABLE 9: REFRACTIVE INDEX AND % TRANSMITTANCE VALUES 
S. 
N
O 
FORMU-
LATION 
REFRACTIVE 
INDEX 
%TRANS-
MITTANCE 
FORMU-
LATION 
REFRAC-
TIVE 
INDEX 
%TRANSMIT-
TANCE 
1 OF1 1.341±0.0004 74.90±0.22 CF1 1.330±0.0004 93.38±0.17 
2 OF2 1.338±0.0004 68.79±0.19 CF2 1.336±0.0004 90.58±0.23 
3 OF3 UNSTABLE UNSTABLE CF3 UNSTABLE UNSTABLE 
4 OF4 1.340±0.0004 85.10±0.2 CF4 1.334±0.0004 91.04±0.20 
5 OF5 UNSTABLE UNSTABLE CF5 UNSTABLE UNSTABLE 
6 OF6 UNSTABLE UNSTABLE CF6 UNSTABLE UNSTABLE 
7 OF7 1.340±0.0004 93.44±0.23 CF7 1.324±0.0004 80.10±0.21 
8 OF8 1.333±0.0004 89.21±0.15 CF8 1.333±0.0004 97.47±0.18 
9 OF9 1.338±0.0004 94.28±0.22 CF9 1.334±0.0004 95.08±0.16 
 
 
 
 
115 
 
TABLE 10:  VISCOSITY MEASUREMENT OF SMEDDS 
S.NO FORMUALTION 
VISCOSITY 
(cps) 
FORMULATION 
VISCOSITY 
(cps) 
1 OF1 0.24540.002 CF1 0.8351±0.003 
2 OF2 0.2476±0.0006 CF2 0.8342±0.004 
3 OF4 0.2438±0.003 CF4 0.8251±0.005 
4 OF7 0.2435±0.003 CF7 0.8234±0.004 
5 OF8 0.2456±0.001 CF8 0.8178±0.005 
6 OF9 0.2928±0.002 CF9 0.8034±0.04 
 
TABLE 11: DRUG CONTENT FOR L-SMEDDS 
 
S.NO FORMULATION 
DRUG CONTENT 
(%) 
FORMULATION 
DRUG CONTENT 
(%) 
1 OF1 96.53±0.04 CF1 96.41±0.10 
2 OF2 95.45±0.12 CF2 95.30±0.16 
3 OF3 97.23±0.05 CF3 92.79±0.16 
4 OF4 97.24±0.10 CF4 95.67±0.12 
5 OF5 97.07±0.17 CF5 96.83±0.13 
6 OF6 97.26±0.22 CF6 97.22±0.14 
7 OF7 96.37±0.14 CF7 97.29 ±0.22 
8 OF8 97.8±0.08 CF8 97.33±0.52 
9 OF9 97.43±0.09 CF9 97.17±0.50 
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           TABLE 13: DRUG CONTENT OF S-SMEDDS FORMULATION 
S.NO FORMULATION 
DRUG CONTENT 
(%) 
FORMULATION
DRUG CONTENT 
(%) 
1 OF1 97.28±0.05 CF1 97.54±0.11 
2 OF2 96.86±0.08 CF2 97.50±0.15 
3 OF3 96.79±0.07 CF3 96.62±0.18 
4 OF4 97.48±0.13 CF4 97.82±0.12 
5 OF5 97.38±0.04 CF5 97.30±0.02 
6 OF6 97.59±0.06 CF6 97.52±0.15 
7 OF7 96.54±0.21 CF7 97.72±0.03 
8 OF8 98±0.09 CF8 98.02±0.07 
9 OF9 92.13±0.09 CF9 97.73±0.08 
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TABLE 12 (a):    CHARACTERIZATION OF MICROMERITIC PROPERTIES OF    S- SMEDDS 
 
 
 
  
S.NO PARAMETER CF1 CF2 CF3 CF4 CF5 CF6 CF7 CF8 CF9 
1 Angle of 
Repose 
28o12’± 
1 O23’ 
28o13± 
0O 43’ 
28o21’± 
0O 21’ 
28021’± 
0 O21’ 
28o14’± 
0O 12’ 
28o26’± 
0 O32’ 
28o34’± 
0O 46’ 
28o38’ 
±1o39’ 
28o31’ ± 
0 O51’ 
2 Bulk density 
g/ml 
0.3422    
± 0.006 
0.3416 
± 0.006 
0.3423 
± 0.006 
0.3381 
± 0.006 
0.3445 
± 0.006 
0.3423 
± 0.006 
0.3427 
± 0.006 
0.3436 
± 0.006 
0.3425 
± 0.006 
3 Tapped 
density 
0.4023 
± 0.001 
0.4034 
± 0.001 
0.4041 
± 0.001 
0.4045 
± 0.001 
0.4021 
± 0.01 
0.4035 
± 0.006 
0.4042 
± 0.006 
0.4043 
± 0.001 
0.4038 
± 0.006 
4 Carr’s index 
% 
15.17 
± 0.001 
15.18 
± 0.001 
15.02 
± 0.001 
15.02 
±0.001 
15.18 
±0.001 
15.12 
±0.001 
15.17 
±0.001 
15.01 
±0.001 
15.18 
±0.001 
5 Hausner’s 
ratio 
1.18
±0.02 
1.17
±0.02 
1.19
±0.02 
1.18
±0.02 
1.17
±0.02 
1.17
±0.02 
1.18
±0.02 
1.17
±0.002 
1.19
±0.02 
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TABLE 12 (B): CHARACTERIZATION OF MICROMERITIC PROPERTIES. 
 
 
S.NO
PARAME-
TER 
OF1 OF2 OF3 OF4 OF5 OF6 OF7 OF8 OF9 
1 
Angle of 
Repose 
28o12± 
1 023’ 
28o13±  
 0 043’ 
28o21± 
 0 021’ 
28021±  
0 021’ 
28o14± 
 0 012’ 
28o26± 
 0 032’ 
28o34±  
 0 046’ 
26o54’± 
1o39’ 
28o31±  
0 051’ 
2 
Bulk 
density 
g/ml 
0.3422   ±  
0.006 
0.3416 
±0.006 
0.3423 
±0.006 
0.3381 
±0.006 
0.3445 
±0.006 
0.3423 
±0.006 
0.3427 
±0.006 
0.3423 
±0.006 
0.3425 
0.006 
3 
Tapped 
density 
0.4023 
±0.001 
0.4034 
±0.001 
0.4041 
±0.001 
0.4045 
±0.001 
0.4021 
±0.01 
0.4035 
±0.006 
0.4042 
±0.006 
0.4040 
±0.001 
0.4038 
±0.006 
4 
Carr’s 
index 
% 
15.17 
±0.001 
15.18 
±0.001 
15.02 
±0.001 
15.02 
±0.001 
15.18 
±0.001 
15.12 
±0.001 
15.17 
±0.001 
15.27 
±0.001 
15.18 
±0.001 
5 
Hausner’s   
ratio 
1.18 ±0.02 1.17 ±0.02 1.19 ±0.02 1.18 ±0.02 1.17 ±0.02 1.17  
±0.02 
1.18 ±0.02 1.18 ±0.02 1.19 ±0.02 
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TABLE 14 (a): CUMULATIVE PERCENTAGE DRUG RELEASE FOR OLEIC ACID SMEDDS FORMULATION FOR 2 HOURS. 
TIME IN 
MINUTES 
    % CUMULATIVE DRUG RELEASE  
OF1 OF2 OF3 OF4 OF5 OF6 OF7 OF8 OF9 
0 0 0 0 0 0 0 0 0 0 
5 67.22 
±0.45 
66.57 
±0.17 
63.56 
±0.18 
63.56 
±0.18 
68.75± 
0.48 
65.07 
±0.36 
69.59 
±0.39 
69.49 
±0.16 
69.19 
±0.511 
10 71.57 
±0.67 
70.21 
±0.53 
66.48 
±0.15 
66.41 
±0.31 
69.73 
±0.23 
66.27 
±0.36 
70.59 
±0.13 
70.41 
±0.17 
70.67 
±0.34 
20 72.07 
±0.15 
71.55 
±0.09 
70.74 
±0.25 
69.6 
8±0.18 
70.3 
7±0.08 
68.02 
±0.27 
71.67 
±0.28 
71.19 
±0.18 
72.96 
±0.20 
30 73.53 
±0.10 
72.52 
±0.13 
71.2 
7±0.13 
70.88 
±0.41 
71.06 
±0.21 
69.86 
±0.31 
72.65 
±0.31 
72.22 
±0.13 
73.55 
±0.13 
45 74.27 
±0.16 
73.31 
±0.23 
71.88 
±0.24 
71.59 
±0.32 
71.98 
±0.34 
71.05 
±0.21 
74.54 
±0.23 
73.20 
±0.12 
75.53 
±0.13 
60 74.72 
±0.07 
74.6 
3±0.17 
73.09 
±0.28 
71.86 
±0.31 
73.1 
1±0.29 
72.71 
±0.37 
76.63 
±0.30 
74.38 
±0.14 
77.01 
±0.40 
80 75.15 
±0.20 
75.67 
±0.21 
74.30 
±0.35 
72.71 
±0.28 
73.97 
±0.26 
74.62 
±0.16 
77.52 
±0.23 
75.63 
±0.17 
79.21 
±0.47 
100 75.66 
±0.30 
76.07 
±0.46 
75.44 
±0.20 
73.46 
±0.20 
74.89± 
0.37 
75.50 
±0.19 
79.06 
±0.46 
76.86 
±0.47 
80.10 
±0.18 
120 76.72 
±0.27 
77.16 
±0.24 
76.39 
±0.25 
74.53 
±0.15 
76.23 
±0.11 
76.59 
±0.14 
80.03 
±0.33 
77.66 
±0.64 
80.52 
±0.12 
 120 
 
 
 
TIME IN 
MINTS 
% CUMULATIVE DRUG RELEASE 
CF1 CF2 CF3 CF4 CF5 CF6 CF7 CF8 CF9 
0 0 0 0 0 0 0 0 0 0 
5 68.98 ±0.31 
63.75 
±0.32 
67.05 
±0.09 
66.46 
±0.10 
70.59 
±0.24 
67.05 
±0.33 
71.22 
±0.14 
71.85 
±0.34 
72.43 
±0.17 
10 70.31 ±0.17 
65.62 
±0.23 
68.18 
±0.32 
67.81 
±0.26 
71.58 
±0.35 
68.12 
±0.25 
72.42 
±0.22 
73.36 
±0.06 
73.74 
±0.20 
20 70.98 ±0.12 
67.25 
±0.43 
70.04 
±0.44 
69.67 
±0.17 
72.70 
±0.24 
69.13 
±0.10 
73.70 
±0.35 
74.65 
±0.18 
75.26 
±0.24 
30 
71.63 
±0.08 
68.59 
±0.13 
70.66 
±0.41 
70.42 
±0.12 
74.36 
±0.65 
70.80 
±0.27 
75.69 
±0.29 
76.25 
±0.59 
77.06 
±0.32 
45 73 ±0.16 
69.76 
±0.31 
73.47 
±0.26 
71.28 
±0.20 
75.74 
±0.35 
72.57 
±0.13 
76.69 
±0.20 
77.27 
±0.50 
78.62 
±0.21 
60 73.62 ±0.13 
71.01 
±0.23 
75.05 
±0.21 
72.26 
±0.47 
76.85 
±0.31 
74.54 
±0.29 
77.61 
±0.34 
79.11 
±0.51 
79.78 
±0.45 
80 75.02 ±0.13 
71.89 
±0.21 
76.67 
±0.20 
73.56 
±0.46 
78.21 
±0.13 
75.57 
±0.37 
78.71±0 
.35 
80.14 
±0.18 
80.59 
±0.22 
100 75.72 ±0.16 
72.85 
±0.27 
78.46 
±0.35 
74.53 
±0.34 
79.40 
±0.22 
76.72 
±0.16 
80.64 
±0.21 
80.93 
±0.17 
81.58 
±0.31 
120 76.46 ±0.10 
74.79 
±0.32 
79.59 
±0.16 
77.02 
±0.24 
80.45 
±0.18 
78.51 
±0.38 
81.77 
±0.21 
82.14 
±0.15 
81.98 
±0.25 
 
TABLE 14 (b): CUMULATIVE PERCENTAGE DRUG RELEASE FOR CAPRYOL SMEDDS FORMULATION FOR 2 HOURS. 
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FORMU 
LATION 
CODE 
ZERO ORDER 
KINETICES 
FIRST OR-
DER KI-
NETICES 
HIGUCHI 
MODEL 
KORSMEY 
ER PEPPAS 
MODEL 
HIXSON 
CROWEL 
MODEL 
R2 K0(h-1) R2 K0(h-1) R2 KH(h-1/2) R2 n R2 KHC(h-1/3)
OF1 0.977 2.382 0.955 -0.038 0.979 18.01 0.973 1.459 0.936 -0.126 
OF2 0.969 2.325 0.960 -0.037 0.981 17.25 0.959 1.524 0.949 -0.118 
OF3 0.969 4.490 0.953 -0.036 0.983 17.18 0.964 1.451 0.944 -0.122 
OF4 0.945 4.113 0.967 -0.031 0.963 15.48 0.936 1.497 0.906 -0.122 
OF5 0.993 3.855 0.941 -0.029 0.992 15.77 0.949 1.452 0.927 -0.107 
OF6 0.963 5.524 0.887 -0.054 0.972 21.31 0.956 1.470 0.921 -0.156 
OF7 0.967 5.613 0.967 -0.054 0.977 21.73 0.959 1.483 0.924 -0.173 
OF8 0.979 5.618 0.961 -0.054 0.966 22.01 0.948 1.453 0.938 -0.079 
OF9 0.976 5.566 0.966 -0.050 0.974 21.73 0.954 1.518 0.932 -0.165 
CF1 0.963 5.381 0.919 -0.049 0.980 20.77 0.953 1.573 0.914 -0.146 
CF2 0.935 5.138 0.954 -0.047 0.978 19.61 0.947 1.541 0.894 -0.107 
CF3 0.971 5.249 0.941 -0.045 0.980 20.44 0.959 1.464 0.939 -0.104 
CF4 0.960 4.995 0.943 -0.043 0.986 19.38 0.976 1.475 0.976 -0.101 
CF5 0.964 5.219 0.930 -0.044 0.984 20.37 0.960 1.471 0.937 -0.089 
CF6 0.965 4.632 0.965 -0.043 0.982 17.76 0.966 1.484 0.971 -0.087 
CF7 0.960 5.820 0.942 -0.038 0.949 22.60 0.942 1.462 0.941 -0.142 
CF8 0.942 6.306 0.953 -0.060 0.989 25.04 0.981 1.520 0.982 -0.144 
CF9 0.900 6.178 0.935 -0.061 0.983 24.54 0.976 1.537 0.980 -0.137 
Table 15:  IN VITRO KINETIC RELEASE STUDIES OF PITAVASTATIN SOLID SMEDDS
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FIGURE 1: DETERMINATION OF λmax FOR PITAVASTATIN CALCIUM 
 
 
 
 
 
 
 
 
 
 
 
S.NO WAVELENGTH ABSORBANCE DESCRIPTION
1 245nm 0.987 10μg/ml 
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FIGURE 1 (a): CALIBRATION CURVE FOR PITAVASTATIN CALCIUM USING 
PHOSPHATE BUFFER pH 6.8. 
 
FIGURE 2 (a): IR SPECTRA OF PURE PITAVASTATIN CALCIUM                   
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FIGURE 2 (b): IR SPECTRA OF OLEIC ACID 
 
FIGURE 2 (c): IR SPECTRA OF CAPRYOL 90 
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FIGURE 2 (d): IR SPECTRA OF TWEEN 80 
 
FIGURE 2 (e): IR SPECTRA OF PROPYLENE GLYCOL 
 
 
 
 
 
  
126 
 
 
FIGURE 2 (f): IR SPECTRA OF MICRO CRYSTALLINE CELLULOSE 
 
TABLE 16: IR INTERPRETATION OF COMPONENTS OF SMEDDS. 
 
S.NO MATERIAL PEAK OBSERVATION 
1 Pitavastatin 3066.82 cm-1, 3003.17 cm-1, 2958.80 cm-1, 1720.50 
cm-1,  1490.97 cm-1,1219.01 cm-1,678.94 cm-1 
2 Oleic acid 3318.90 cm-1, 2989.66 cm-1,  2881 cm-1,1708.93 cm-1, 
1462.4 cm-1, 1408 cm-1, 709.8 cm-1 
3 Capryol 90 3421 cm-1, 2928 cm-1,2871 cm-1 
4 Tween 80 3599.17 cm-1 , 2924.09 cm-1 , 1734.01 cm-1  , 1111 
cm-1 
5 Propylene glycol 3375.43 cm-1 , 2972 cm-1, 2933.73 cm-1,1379.10 cm-1 , 
1080.14 cm-1 , 1045.42 cm-1 
6. MCC 102 3302.13 cm-1, 2900.94 cm-1, 1620.21 cm-1, 1500.62 
cm-1 , 1431.18 cm-1 
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FIGURE 5 (a).% TRANSMITTANCE  WITH OLEIC ACID
% transmittance
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FIGURE 6 : PHASE DIAGRAM FOR OLEIC ACID & TWEEN 80: PROPYLENE 
GLYCOL 
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FIGURE 6 (a): SMIXTURE RATIO OF 1:1 
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FIGURE 6 (b): SMIXTURE RATIO OF 2:1 
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FIGURE 6 (c): S MIXTURE RATIO OF 3:1 
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     FIGURE 7: PHASE DIAGRAM FOR CAPRYOL 90 AND CREMO-
PHORE:PROPYLENE GCOL 
 
FIGURE 7 (a): SMIXTURE RATIO OF 1:1 
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FIGURE 7 (b): SMIXTURE RATIO OF 2:1 
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FIGURE 7 (C): SMIXTURE RATIO OF 3:1 
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FIGURE 10 : COMPARISION OF IN VITRO RELEASE OF S-SMEDDS OF 
PITAVASTATIN-CAPRYOL FORMULATION 
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FIGURE 11: COMPARISION OF IN VITRO RELEASE OF S-SMEDDS OF 
PITAVASTATIN-OLEIC ACID FORMULATION 
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FIGURE 12 : COMPARISION OF IN VITRO DRUG RELEASE OF PURE DRUG, 
CONVENTIONAL TABLET AND SMEDDS FORMULATION 
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FIGURE 13.COMPARISION OF IN VITRO ZERO ORDER KINETICS OF 
PITAVASTATIN SMEDDS  
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FIGURE 14.COMPARISION OF IN VITRO FIRST ORDER KINETICS OF 
PITAVASTATIN SMEDDS  
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FIGURE 15.COMPARISION OF IN VITRO HIGUCHI MODEL RELEASE KINET-
ICS OF 
 PITAVASTATIN SMEDDS  
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FIGURE 16: COMPARISION OF IN VITRO KORSEMEYER PEPPAS MODEL                         
RELEASE KINETICS OF PITAVASTATIN SMEDDS. 
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FIGURE 17. COMPARISION OF IN VITRO HIXON CROWEL MODEL RELEASE 
KINETICS OF PITAVASTATIN SMEDDS 
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FIGURE 17 (a). HIXSON CROWEL MODEL 
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FIGURE 18: FTIR SPECTRA 
FIGURE 18 (a):  FTIR SPECTRA OF PURE PITAVASTATIN CALCIUM 
 
FIGURE 18 (b): FTIR SPECTRA OF LIQUID SMEDDS OF PITAVASTATIN US-
ING OLEIC ACID, TWEEN 80 AND PROPYLENE GLYCOL 
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FIGURE 18 (c): FTIR SPECTRA OF LIQUID SMEDDS OF PITAVASTATIN US-
ING CAPRYOL 90, CREMOPHORE RH 40 AND PG 
 
FIGURE 18 (d): FTIR SPECTRA OF SOLID SMEDDS OF PITAVASTATIN US-
ING OLEIC ACID, TWEEN 80 AND PG 
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FIGURE 18 (e): FTIR SPECTRA OF SOLID SMEDDS OF PITAVASTATIN US-
ING CAPRYOL 90, CREMOPHORE RH 40 AND PG 
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FIGURE 19 (a): SEM IMAGE OF PURE PITAVASTATIN CALCIUM 
 
FIGURE 19 (b): SEM IMAGE OF PREPARED SOLID SMEDDS OF PITAVAS-
TATIN 
 
 
 
 
 
 
  
153 
 
 
 
FIGURE 20 (a): PXRD PATTERN SMEDDS FORMULATION 
 
FIGURE 20 (b): PXRD PATTERN OF PURE DRUG 
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FIGURE 21: ZETA POTENTIAL ANALYSIS 
FIGURE 21 (a): ZETA POTENTIAL CURVE FOR CF8 
 
 
FIGURE 21 (b): ZETA POTENTIAL CURVE FOR OF9 FORMULATION 
`  
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FIGURE 21 (C) : PARTICLE SIZE DISTRIBUTION FOR CF8 
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FIGURE 22 : DSC THERMOGRAM OF BEST FORMULATION 
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CHAPTER – XI 
SUMMARY AND CONCLUSION 
 
• In the present study, an attempt has been made to develop Self Micro 
Emulsifying Drug Delivery system of Pitavastatin in order to enhance the 
solubility and dissolution rate by incorporating the drug in a lipid vehicle. 
• The results of compatability studies by Infrared spectroscopy and 
differential scanning calorimetry (DSC), showed no interaction 
between the drug and excipients. 
• Various oils, surfactants and co-surfactants are optimized based on their 
solulbilising capacity and % transmittance values. 
• The solubility of Pitavastatin was found to higher in oleic acid 
(97.89%±0.06) and Capryol 90 (93.69%±0.31) 
• Pseudo ternary phase diagrams were constructed to get the maximum self 
emulsification region of SMEDDS, and the optimum concentration of oil 
was found to be 10-50% and Smixture was found to be 50-90% for both oils. 
• Two different type of Pitavastatin liquid SMEDDS were successfully 
prepared at different ratios of oil, surfactant and co-surfactant by simple 
admixing method, namely CF1-CF9 and OF1-OF9. 
• The prepared SMEDDS were evaluated for their physiochemical 
parameters. (Dispersibility test, visual assessment, self emulsification 
time, % transmittance and Refractive index). 
• The RI of formulation ranges from 1.333 to 1.348. 
• The % transmittance value for all the formulation ranges from 68 -97%. 
And the formulation which shown % transmittance value of above 90% 
provides clear emulsion. CF8 and OF8 shows maximum % transmittance 
(97.47±0.18% and 94.28±0.22%) 
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• The drug content of liquid SMEDDS ranges from 92- 98 %. Formulation 
CF8 and OF8 shown maximum drug content. (98.02±0.07% and 
98.23±0.17% respectively) 
• Then the liquid SMEDDS were converted into S-SMEDDS by adsorption 
technique by mixing it with Micro crystalline Cellulose at 1:1 w/w ratio. 
• In vitro release study of all the formulations were shown an increased drug 
release. Dissolution rate of all the formulations were improved when 
compared to pure drug. 
• The dissolution study was carried out in pH 6. 8 buffer for 2 hours. The 
formulations shown higher rate of drug release than that of the pure drug 
and marketed formulation, and all formulations showed 60-82% of drug 
release within two hours. Formulation OF8 and CF8 shows 
80.52±0.12% and 82.14±0.15% respectively, which is higher rate than 
the pure drug (59.25±0.20%) and conventional tablet (64.72±0.21%) 
• Particle size analyzer used to explore the particle size of Pitavastatin 
SMEDDS showed a suitable particle size of 139.5 nm and 0.621nm for 
OF8 and CF8 respectively. 
• The polydispersibility index of selected SMEDDS formulations (CF8 & OF8) 
were 0.377 and 0.291, which indicated a broad size distribution of 
particles. 
• Zeta potential value of Pitavastatin SMEDDS showed a negative surface 
charge (- 23.9mv and -20.9mv). 
• SEM studies confirmed the morphology of the solid SMEDDS. 
• The crystalline state of the formulation was altered according to the XRPD 
analysis. It confirms the solubilisation of drug. 
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CONCLUSION 
Pitavastain is a poorly water soluble drug, and its bioavailability is only 
about 60% due it is poor solubility. When administering this poorly soluble 
compound with hydrophilic carriers will enhance the solubility of the drug. 
Hence, it was concluded that Self Micro Emulsifying drug delivery 
system is a good approach to enhance the solubility and dissolution property 
of Pitavastatin. The composition of optimized formulation [CF8  consist of 
Capryol 90 as oil(45%), Cremophore RH(41.2%) as surfactant and Propylene 
glycol(13.75%) as co-surfactant and OF8 consist of Oleic acid (45%), Tween 
80 (41.2%) and Propylene glycol (13.75%)] containing 4mg of Pitavastatin 
calcium showing drug release for solid SMEDDS formulation (82.14% & 
80.52%), Particle size (139.5 nm & 621.3nm), Zeta potential (-23.29 & -20.9), 
viscosity (0. 8824 cP). In-vitro drug release of the C8 and OF8 was highly 
significant compared to pure drug and marketed conventional tablet. Here the 
liquid SMEDDS are successfully converted into solid SMEDDS using MCC by 
adsorption technique. 
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